Antibody-drug Conjugate/ADC Related

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.
[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Target List in Antibody-drug Conjugate/ADC Related

ADC Cytotoxin

ADC Payload

ADC cytotoxins (also known as payloads) are cytotoxic agents that induce target cell death in Antibody Drug Conjugates (ADCs). An ADC is a targeted agent composed with a monoclonal antibody, a linker and a cytotoxin. The cytotoxin is the most important component as it determines the potency to kill cancer cells of an ADC.

There are many cytotoxins which are currently being used such as Calicheamicins, Duocarmycins, Pyrrolobenzodiazepines (PBDs), Camptothecins, Daunorubicins/Doxorubicins, Auristatins and Maytansinoids. They can be divided in two classes based on their mechanism of action, DNA damaging agents and tubulin inhibitors. Among them Calicheamicins, Duocarmycins and PBDs are DNA minor grove binders, Camptothecins and Daunorubicins/Doxorubicins are topoisomerase inhibitors, which are DNA damaging agents. Auristatins and Maytansinoids are tubulin inhibitors. Except for the listed cytotoxins, there are numbers of traditional cytotoxic agents with similar mechanisms of killing cancer cells and can also be used in the development of ADCs.

ADC Cytotoxin

(+)-CBI-CDPI1

Cat. No.: HY-128880

(+)-CBI-CDPI1 is an enhanced functional analog of CC-1065. (+)-CBI-CDPI1 is a DNA alkylating agent. (+)-CBI-CDPI1 is an antibody drug conjugates (ADCs) toxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(+)-CBI-CDPI2

Cat. No.: HY-128881

(+)-CBI-CDPI2 is an enhanced functional analog of CC-1065. (+)-CBI-CDPI1 is a DNA alkylating agent. (+)-CBI-CDPI2 is an antibody drug conjugates (ADCs) toxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Seco-Duocarmycin SA

Cat. No.: HY-129356A

(S)-Seco-Duocarmycin SA is a **DNA alkylator**, cytotoxic to cancer cells, and acts as a **ADC cytotoxin** for antibody-drug conjugates.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

10-Deacetyl-7-xylosyl paclitaxel (10-Deacetyl-7-xylosyltaxol; 10-Deacetylpaclitaxel 7-Xyloside; ...)

Cat. No.: HY-20584

10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel (a microtubule stabilizing agent; enhances tubulin polymerization) derivative with improved pharmacological features.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

17-AEP-GA

Cat. No.: HY-133570

17-AEP-GA, an **HSP90** antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. ADCs Toxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

17-GMB-APA-GA

Cat. No.: HY-130997

17-GMB-APA-GA is an **ADC Cytotoxin**. 17-GMB-APA-GA is a potent **HSP90** inhibitor and used for latent T. gondii infection research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2',3'-cGAMP-C2-SH

Cat. No.: HY-141663

2',3'-cGAMP-C2-SH is a ADC cytotoxin that is extracted from patent US20210015941, example 24.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Aminomethyl-10-methyl-11-fluoro camptothecin

Cat. No.: HY-132160

7-Aminomethyl-10-methyl-11-fluoro camptothecin is a cytotoxin of MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (HY-132158compound 21a).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-MAD-MDCPT

Cat. No.: HY-132162

7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aeruginosin 865

Cat. No.: HY-130994

Aeruginosin 865, isolated from terrestrial cyanobacterium Nostoc sp. Lukešová 30/93, is the first aeruginosin-type peptide containing both a fatty acid and a carbohydrate moiety. Aeruginosin 865 inhibits translocation of **NF-kB** to the nucleus.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Agrochelin

Cat. No.: HY-130995

Agrochelin, an alkaloid cytotoxic **antibiotic**, is produced by the fermentation of a marine Agrobacterium sp. Agrochelin has cytotoxic activity in tumor cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Aldoxorubicin

(INNO-206; DOXO-EMCH)

Cat. No.: HY-16261

Aldoxorubicin (INNO-206) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.



Purity: 95.99%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Aminohexylgeldanamycin

(AHGDM)

Cat. No.: HY-133571

Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent **HSP90** inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Aminohexylgeldanamycin hydrochloride

(AHGDM hydrochloride)

Cat. No.: HY-133571A

Aminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent **HSP90** inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aniline-MPB-amino-C3-PBD

Cat. No.: HY-135900

Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group.
Aniline-MPB-amino-C3-PBD is a sequence-selective **DNA** minor-groove binding agent.
Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ansamitocin P 3'

(Antibiotic C 15003P3'; Maytansinol butyrate)

Cat. No.: HY-19839

Ansamitocin P 3' exhibits antitumour activity, is an antibody drug conjugate cytotoxin. The more information please refer to Ansamitocin P-3 (HY-15739, a tubulin inhibitor).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ansamitocin P-3

(Antibiotic C 15003P3; Maytansinol isobutyrate)

Cat. No.: HY-15739

Ansamitocin P-3 (Antibiotic C 15003P3) is a **microtubule** inhibitor. Ansamitocin P-3 is a macrocyclic antitumor antibiotic.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Auristatin E

Cat. No.: HY-15582

Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Auristatin F

Cat. No.: HY-15583

Auristatin F is a potent **cytotoxin**. Auristatin F, a potent **microtubule** inhibitor and vascular damaging agent (VDA), can be used in antibody-drug conjugates (ADC).



Purity: 99.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Azonafide-PEABA

Cat. No.: HY-126664

Azonafide-PEABA is a cytotoxic drug moiety.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-11

Cat. No.: HY-100861

C-11 is a **tubulin inhibitor** and acts as an **ADC cytotoxin**, displays cytotoxicity for carcinoma cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calicheamicin

(Calicheamicin γ1)

Cat. No.: HY-19609

Calicheamicin, an **antitumor antibiotic**, is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin is a **DNA synthesis** inhibitor.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Camptothecin

(Campathecin; (S)-(+)-Camptothecin; CPT)

Cat. No.: HY-16560

Camptothecin (CPT), a kind of alkaloid, is a **DNA topoisomerase I (Topo I) inhibitor** with an IC_{50} of 679 nM.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Camptothecin-d5

(Campathecin-d5; (S)-(+)-Camptothecin-d5; CPT-d5)

Cat. No.: HY-16560S

Camptothecin-d5 (Campathecin-d5) is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a **DNA topoisomerase I (Topo I) inhibitor** with an IC_{50} of 679 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CC-885-CH2-PEG1-NH-CH3

Cat. No.: HY-145449

CC-885-CH2-PEG1-NH-CH3 is a neoDegrader that can be used in the synthesis of **Antibody neoDegrader Conjugate (AnDC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Corixetan

Cat. No.: HY-132851

Corixetan is a highly efficient thorium chelator. Corixetan can efficiently complex Th-227 with sufficient in vivo stability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D8-MMAF

(Monomethylauristatin F D8)

Cat. No.: HY-15579S

D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride. MMAF Hydrochloride, a potent tubulin polymerization inhibitor, is used as a antitumor agent and a cytotoxic component of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daun02

Cat. No.: HY-13061

Daun02 is a prodrug of the **topoisomerase** inhibitor Daunorubicin.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Daunorubicin

(Daunomycin; RP 13057; Rubidomycin)

Cat. No.: HY-13062A

Daunorubicin (Daunomycin; RP 13057; Rubidomycin) is a **topoisomerase II** inhibitor with potent antineoplastic activities. Daunorubicin (Daunomycin; RP 13057; Rubidomycin) inhibits **DNA and RNA synthesis** in sensitive and resistant Ehrlich ascites tumor cells.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Daunorubicin hydrochloride (Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride)

Cat. No.: HY-13062

Daunorubicin (Daunomycin) hydrochloride is a **topoisomerase II** inhibitor with potent antineoplastic activities. Daunorubicin hydrochloride inhibits **DNA and RNA synthesis** in sensitive and resistant Ehrlich ascites tumor cells.



Purity: 99.23%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

DC0-NH2

Cat. No.: HY-129379

DC0-NH2 is an effector moiety for **ADC** and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer drugs (ex. Doxorubicin).



Purity: 95.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

DC1

Cat. No.: HY-112899

DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

DC10SMe

Cat. No.: HY-135122

DC10SMe is a **DNA alkylator**, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC10SMe exhibits IC_{50}s of 15 pM, 12 pM, and 12 pM for Ramos, Namalwa, and HL60/s cancer cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DC1SMe

Cat. No.: HY-112898

DC1Sme, a DC1 derivative, exhibits IC_{50} values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DC4

Cat. No.: HY-135125

DC4, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC4 can be used for the targeted treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DC41

Cat. No.: HY-112901

DC41 is a DC1 derivative. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DC41SMe

Cat. No.: HY-112900

DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with **IC_{50}**s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DC44SMe

Cat. No.: HY-135124

DC44SMe, a phosphate prodrug of cytotoxic DNA alkylator DC44, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC44SMe exhibits IC_{50}s of 2.0 nM, 2.8 nM, and 1.9 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DC4SMe

Cat. No.: HY-135123

DC4SMe, a phosphate prodrug of cytotoxic DNA alkylator DC4, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC4SMe exhibits IC_{50}s of 1.9 nM, 2.9 nM, and 1.8 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diacetyl Agrochelin

Cat. No.: HY-130996

Diacetyl Agrochelin is an acetyl derivative of Agrochelin, which is produced by the fermentation of a marine Agrobacterium sp. Diacetyl Agrochelin has cytotoxic activity in tumor cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Dimethyl-SGD-1882

(Dimethyl-PBD dimer)

Cat. No.: HY-126678

Dimethyl-SGD-1882 (Dimethyl-PBD dimer) is a highly potent DNA alkylator, and is used as an antibody-drug conjugate (ADC) cytotoxin. PBD Dimer is a DNA alkylator which inhibits DNA replication.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM1-SMe

Cat. No.: HY-100128

DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent drug Maytansine, with IC_{50}s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM3

(Maytansinoid DM3)

Cat. No.: HY-130080

DM3 (Maytansinoid DM3) is a maytansine analog bearing disulfide or thiol groups and a **tubulin** inhibitor, and is a cytotoxic moiety of **antibody-drug conjugates (ADCs)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DM3-SMe

Cat. No.: HY-130081

DM3-SMe is a maytansine derivative and a **tubulin** inhibitor, and is a cytotoxic moiety of **antibody-drug conjugates (ADCs)**, which can be linked to antibody through disulfide bond or stable thioether bond.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

DM4

Cat. No.: HY-12454

DM4 is is an **antitubulin** agent that inhibit cell division. DM4 can be used in the preparation of antibody drug conjugate.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

DM4-d6

Cat. No.: HY-12454S

DM4-d6 is deuterium labeled DM4. DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM4-SMe

Cat. No.: HY-130082

DM4-SMe is a metabolite of **antibody-maytansin conjugates (AMCs)** and a **tubulin** inhibitor, and also a cytotoxic moiety of **antibody-drug conjugates (ADCs)**, which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an **IC_{50}** of 0.026 nM.



Purity: 95.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

DMEA-PNU-159682

Cat. No.: HY-126665

DMEA-PNU-159682 (molecule D12) is a **ADC cytotoxin** molecule including metabolites of nemorubicin (MMDX) from liver microsomes and a potent ADCs cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dolastatin 10

(DLS 10; NSC 376128)

Cat. No.: HY-15580

Dolastatin 10 (DLS 10) is a potent antimitotic peptide that inhibits **tubulin** polymerization.



Purity: 98.63%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Dolastatin 15

(DLS 15)

Cat. No.: HY-P1126

Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent **antimitotic** agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doxorubicin

(Hydroxydaunorubicin) Cat. No.: HY-15142A

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits **topoisomerase II** with an IC_{50} of 2.67 μM, thus stopping DNA replication.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Doxorubicin hydrochloride

(Hydroxydaunorubicin hydrochloride) Cat. No.: HY-15142

Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human **DNA topoisomerase I** and **topoisomerase II** inhibitor with IC_{50}s of 0.8 μM and 2.67 μM, respectively.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

DRF-1042

Cat. No.: HY-125331

DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit **DNA topoisomerase I**. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Duocarmycin A

Cat. No.: HY-12455

Duocarmycin A, which is one of well-known antitumor antibiotics, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Duocarmycin Analog

Cat. No.: HY-129355

Duocarmycin Analog is an analog of Duocarmycin, and used as an **DNA alkylator** and **ADC cytotoxin**.



Purity: 95.85%
Clinical Data: No Development Reported
Size: 1 mg

Duocarmycin DM

Cat. No.: HY-130978

Duocarmycin DM, a **DNA minor-groove alkylator**, is an antibody drug conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Duocarmycin DM free base

Cat. No.: HY-128915

Duocarmycin DM free base, a **DNA minor-groove alkylator**, is an antibody drug conjugates (ADCs) toxin. Duocarmycin DM free base is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Duocarmycin GA

Cat. No.: HY-128873

Duocarmycin GA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-drug resistant cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Duocarmycin MA

Cat. No.: HY-18987

Duocarmycin MA is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MA can be used against multi-drug resistant cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Duocarmycin MB

Cat. No.: HY-107770

Duocarmycin MB is an antibody drug conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MB can be used against multi-drug resistant cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Duocarmycin SA

Cat. No.: HY-12456

Duocarmycin SA is a potent antitumor antibiotic with an **IC_{50}** of 10 pM. Duocarmycin SA is an extremely potent **cytotoxic** agent capable of inducing a sequence-selective **alkylation** of duplex DNA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Duocarmycin TM

Cat. No.: HY-107769

Duocarmycin TM is an exceptionally potent antitumor antibiotic. Duocarmycin TM is a DNA alkylator.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Duostatin 5

Cat. No.: HY-145149

Duostatin 5 is a **cytotoxin** designed based on dolastatin, can meet the requirement of serving as an effective cytotoxin in **ADC**, but has the advantages of fewer synthesis steps, easy operation, less difficulty in quality control and more stable chemical synthesis process.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dxd

(Exatecan derivative for ADC)

Cat. No.: HY-13631D

Dxd (Exatecan derivative for ADC) is a potent **DNA topoisomerase I** inhibitor, with an **IC_{50}** of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Dxd-d5

(Exatecan-d5 derivative for ADC)

Cat. No.: HY-13631DS

Dxd-D5 (Exatecan-D5 derivative for ADC) is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC_{50} of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Eribulin

(B1939; E7389; ER-086526)

Cat. No.: HY-13442

Eribulin (E7389) is a **microtubule** targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.



Purity: 99.80%
Clinical Data: Launched
Size: 500 μg, 1 mg, 5 mg, 10 mg

Fmoc-MMAE

Cat. No.: HY-78933

Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

Hemiasterlin derivative-1

Cat. No.: HY-145148

Hemiasterlin derivative-1 is a hemiasterlin derivative. Hemiasterlin derivative-1 can be used for the synthesis of the Antibody-drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hygrolidin

Cat. No.: HY-133537

Hygrolidin is a 16-membered macrolide **antibiotic** produced by Streptomyces hygroscopicus D-1166. Hygrolidin has **anti-fungus** activity against Valsa ceratosperma. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Hygrolidin has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Isofistularin-3

Cat. No.: HY-19826

Isofistularin-3 is a direct, DNA-competitive **DNMT1** inhibitor, with an **IC_{50}** of 13.5 μM. Isofistularin-3, as a DNA demethylating agent, induces cell cycle arrest and sensitization to TRAIL in cancer cells. Isofistularin-3 can be used as an ADC cytotoxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Luisol A

Cat. No.: HY-126708

Luisol A, an aromatic tetraol, is a major metabolite of an estuarine marine actinomycete of the genus Streptomyces. Luisol A, anthraquinone antibiotic analog, is an **ADC Cytotoxin**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Maytansinoid DM4

Cat. No.: HY-100503

Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Maytansinol

(Ansamitocin P-0)

Cat. No.: HY-19474

Maytansinol inhibits microtubule assembly and induces microtubule disassembly in vitro. Target: Microtubule/Tubulin in vitro: Maytansinol disrupts the mitotic spindle and prevents mitotic exit in Drosophila.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin

Cat. No.: HY-132158

MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin **antibody-drug conjugate (ADC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mensacarcin

Cat. No.: HY-122534

Mensacarcin, a highly complex polyketide, strongly inhibits cell growth universally in cancer cell lines and potently induces **apoptosis** in melanoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mertansine

(DM1; Maytansinoid DM1)

Cat. No.: HY-19792

Mertansine (DM1) is a **microtubulin** inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.



Purity: 99.80%
Clinical Data: Phase 2
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Methotrexate

(Amethopterin; CL14377; WR19039)

Cat. No.: HY-14519

Methotrexate (Amethopterin), an **antimetabolite** and **antifolate** agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methotrexate disodium (Amethopterin disodium; CL14377 disodium; WR19039 disodium)

Cat. No.: HY-14519A

Methotrexate (Amethopterin) disodium, an **antimetabolite** and **antifolate** agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.



Purity: 98.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methotrexate-d3

Cat. No.: HY-14519S

Methotrexate-d3 (Amethopterin-d3) is the deuterium labeled Methotrexate.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

MMAD (Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10)

Cat. No.: HY-15581

MMAD is a potent **tubulin** inhibitor, is a toxin payload in antibody drug conjugates (**ADCs**).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

MMAD-d8 (Demethyldolastatin 10-d8; Monomethylauristatin D-d8; Monomethyl Dolastatin 10-d8)

Cat. No.: HY-15581S

D8-MMAD is a deuterated form of MMAD, which is a **microtubule** disrupting agent.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MMAE-d8

(Monomethyl auristatin E-d8; Deuterated labeled MMAE)

Cat. No.: HY-15162A

D8-MMAE (D8-Monomethyl auristatin E) is a deuterated labeled MMAE, a potent **mitotic** inhibitor and a tubulin inhibitor.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mg

MMAF

(Monomethylauristatin F)

Cat. No.: HY-15579

MMAF (Monomethylauristatin F) is a potent **tubulin polymerization** inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (**ADC**s) such as vorsetuzumab mafodotin and SGN-CD19A.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMAF hydrochloride

(Monomethylauristatin F hydrochloride)

Cat. No.: HY-15579A

MMAF (Monomethylauristatin F) hydrochloride is a potent **tubulin polymerization** inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (**ADC**s) such as Vorsetuzumab mafodotin and SGN-CD19A.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMAF sodium

(Monomethylauristatin F sodium)

Cat. No.: HY-15579B

MMAF sodium (Monomethylauristatin F sodium) is a potent **tubulin polymerization** inhibitor and is used as a antitumor agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMAF-d8 hydrochloride

Cat. No.: HY-15579AS

D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride, which is a **microtubule** disrupting agent.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MMAF-OMe

(Monomethyl auristatin F methyl ester)

Cat. No.: HY-79256

MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC_{50}s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji ($5T4^-$) cell lines, respectively.



Purity: 96.68%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

Monomethyl auristatin E

(MMAE; SGD-1010; Vedotin)

Cat. No.: HY-15162

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent **mitotic** inhibitor by inhibiting **tubulin** polymerization.



Purity: 99.92%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Muscotoxin A

Cat. No.: HY-131058

Muscotoxin A is an **ADC cytotoxin**. Muscotoxin A is a cytotoxic lipopeptide that permeabilizes mammalian cell membranes and induces necrotic cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mytoxin B

Cat. No.: HY-131055

Mytoxin B is an **ADC cytotoxin**. Mytoxin B is a satratoxin-type trichothecene macrolide and is similar to the effect of LY294002 (HY-10108). Mytoxin B induces cell **apoptosis** via PI3K/Akt pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Me-L-Ala-maytansinol

Cat. No.: HY-126663

N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used for making antibody-drug conjugate (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Paclitaxel

Cat. No.: HY-B0015

Paclitaxel is a naturally occurring antineoplastic agent and stabilizes **tubulin** polymerization. Paclitaxel can cause both mitotic arrest and **apoptotic** cell death. Paclitaxel also induces **autophagy**.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Paclitaxel-d5

Cat. No.: HY-B0015S

Paclitaxel-d5 is a **deuterium-labeled** Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Paclitaxel-d5 (benzoyloxy)

Cat. No.: HY-B0015S1

Paclitaxel-d5 benzoyloxy is the deuterium labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes **tubulin** polymerization. Paclitaxel can cause both mitotic arrest and **apoptotic** cell death. Paclitaxel also induces **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06380101

(Aur0101; Auristatin-0101)

Cat. No.: HY-12522

PF-06380101 (Aur0101), an auristatin **microtubule** inhibitor, is a cytotoxic Dolastatin 10 analogue.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-06380101-d8

(Aur0101-d8; Auristatin-0101-d8)

Cat. No.: HY-12522S

PF-06380101 D8 (Aur0101 D8) is a deuterium labeled PF-06380101. PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Piericidin A

(AR-054)

Cat. No.: HY-114936

Piericidin A (AR-054) is a natural mitochondrial **NADH-ubiquinone oxidoreductase (complex I)** inhibitor. Piericidin A is a potent neurotoxin and inhibits mitochondrial respiration by disrupting the electron transport system through its action on **NADH-ubiquinone reductase**.

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg (12.03 mM * 200 µL in Ethanol),

PNU-159682

Cat. No.: HY-16700

PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent **DNA topoisomerase II** inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated **ADC cytotoxin** than Doxorubicin for ADC synthesis.



Purity: 97.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

PNU-159682 carboxylic acid

Cat. No.: HY-126666

PNU-159682 carboxylic acid (compound 53) is a potent **ADCs cytotoxin** and encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Polyketomycin

Cat. No.: HY-106338

Polyketomycin is a tetracyclic quinone glycoside antibiotic isolated from Streptomyces sp. or Streptomyces diastatochromogenes. Polyketomycin inhibits growth of **Gram-positive bacteria**, and its MIC values is less than 0.2 µg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC BRD4 Degrader-10

Cat. No.: HY-138633

PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 1.3 nM and 18 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-11

Cat. No.: HY-138634

PROTAC BRD4 Degrader-11 (compound 9a) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-11 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.23 nM and 0.38 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-12

Cat. No.: HY-138635

PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.39 nM and 0.24 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-13

Cat. No.: HY-138636

PROTAC BRD4 Degrader-13 (compound 9d) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-13 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.025 nM and 6.0 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC BRD4 Degrader-5-CO-PEG3-N3

Cat. No.: HY-133736

PROTAC BRD4 Degrader-5-CO-PEG3-N3 (Compound 2) is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader GNE-987 and PEG-based linker.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mg

PROTAC BRD4 Degrader-9

Cat. No.: HY-138632

PROTAC BRD4 Degrader-9 (compound 8a) is a PROTAC connected by ligands for **von Hippel-Lindau** and **BRD4**. PROTAC BRD4 Degrader-9 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC_{50} of 0.86 nM and 7.6 nM, respectively.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Py-MPB-amino-C3-PBD

Cat. No.: HY-135901

Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rebeccamycin

Cat. No.: HY-19825

Rebeccamycin, an antitumor antibiotic, inhibits **DNA topoisomerase I**. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

S-methyl DM1

Cat. No.: HY-100504

S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to **tubulin** with a K_d of 0.93 μM and inhibits **microtubule** polymerization. S-methyl DM1 potently suppresses **microtubule** dynamic instability and has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Sandramycin

Cat. No.: HY-19829

Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an **ADC cytotoxin**. Sandramycin is active against **Gram-positive bacteria** and has potent antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

SC209

Cat. No.: HY-144880

SC209, an **ADC cytotoxin** extracted from patent WO2021247798, is used in synthesis of anti-**EGFR** antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Seco-DUBA

Cat. No.: HY-132180A

Seco-DUBA is a duocarmycin (DUBA) prodrug containing two hydroxyl groups, which can each be used for coupling to an antibody via a linker. Seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 95.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Seco-DUBA hydrochloride

Cat. No.: HY-132180

Seco-DUBA hydrochloride is a toxin for ADC drug SYD985.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Seco-Duocarmycin SA

Cat. No.: HY-129356

Seco-Duocarmycin SA is a **DNA alkylator**, and is used as an **ADC cytotoxin**.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

Seco-Duocarmycin TM

Cat. No.: HY-130083

Seco-Duocarmycin TM is a **DNA alkylator** agent belonging to Duocarmycins family that inhibits DNA synthesis. Seco-Duocarmycin TM is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates (ADC)</suo>.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg

SG3199

Cat. No.: HY-101161

SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249).



Purity: 98.94%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SGD-1882

(PBD dimer)

Cat. No.: HY-101127

SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

Purity: 98.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SJG-136

(NSC-694501)

Cat. No.: HY-14573

SJG-136 is a **DNA cross-linking** agent, with an XL_{50} of 45 nM for pBR322 DNA. SJG-136 has potent antitumor activity.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SN-38

(NK012)

Cat. No.: HY-13704

SN-38 (NK012) is an active metabolite of the **Topoisomerase I** inhibitor Irinotecan. SN-38 (NK012) inhibits **DNA** and **RNA synthesis** with IC_{50}s of 0.077 and 1.3 μM, respectively.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

SN-38-d3

(NK012-d3)

Cat. No.: HY-13704S

SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the **Topoisomerase I** inhibitor Irinotecan. SN-38 (NK012) inhibits **DNA** and **RNA synthesis** with IC_{50}s of 0.077 and 1.3 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

SN-38-d5

(NK012-d5)

Cat. No.: HY-13704S1

SN-38-d5 is deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

sulfo-DGN462 sodium

Cat. No.: HY-101150A

sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taltobulin

(HTI-286; SPA-110)

Cat. No.: HY-15584

Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent **antimicrotubule** agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Taltobulin hydrochloride

(HTI-286 hydrochloride; SPA-110 hydrochloride)

Cat. No.: HY-15584B

Taltobulin hydrochloride (HTI-286 hydrochloride), a synthetic analogue of the tripeptide hemiasterlin, is a potent **antimicrotubule** agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Taltobulin trifluoroacetate

(HTI-286 trifluoroacetate; SPA-110 trifluoroacetate)

Cat. No.: HY-15584A

Taltobulin trifluoroacetate (HTI-286 trifluoroacetate), a synthetic analogue of the tripeptide hemiasterlin, is a potent **antimicrotubule** agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Thailanstatin A

Cat. No.: HY-129589

Thailanstatin A is an ultra-potent inhibitor of eukaryotic **RNA splicing** (IC_{50}=650 nM).



Purity: 98.00%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Top1 inhibitor 1

Cat. No.: HY-126142

Top1 inhibitor 1 (compound 28) is a potent human **topoisomerase I (Top1)** inhibitor with an IC_{50} value of 29 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tubulysin A

(TubA)

Cat. No.: HY-15995

Tubulysin A(TubA) is a myxobacterial product that can function as an antiangiogenic agent in many in vitro assays; anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tubulysin IM-1

Cat. No.: HY-130958

Tubulysin IM-1 is an **ADC Cytotoxin** and tubulin binder used as **anti-microtubule toxins**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tubulysin IM-2

Cat. No.: HY-130959

Tubulysin IM-2 is an **ADC Cytotoxin** and tubulin binder used as **anti-microtubule toxins**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tubulysin IM-3

Cat. No.: HY-130960

Tubulysin IM-3 is an **ADC Cytotoxin** and tubulin binder used as **anti-microtubule toxins**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Amanitin

(α-Amatoxin)

Cat. No.: HY-19610

α-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting **RNA-polymerase II**.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg, 1 mg, 2 mg, 5 mg

β-Amanitin

Cat. No.: HY-125586

β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic **RNA polymerase II** and **III**. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs).



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 1 mg

γ-Amanitin

Cat. No.: HY-131081

γ-Amanitin an **ADC cytotoxin** and isolated from the mushroom. γ-Amanitin inhibits **RNA polymerase II** and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

ε-Amanitin

Cat. No.: HY-131083

ε-Amanitin, a cyclic peptide isolated from a variety of mushroom species, potently binds to and inhibits the activity of **RNA polymerase II**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ADC Linkers

Antibody-drug conjugates linkers

Antibody-drug conjugates (ADCs) consist of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs' stability during the preparation and storage stages of the ADCs and during the systemic circulation period.

The ADCs currently undergoing clinical evaluation contain linkers are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, such as reduction in the cytoplasm, exposure to acidic conditions in the lysosome, or cleavage by specific proteases within the cell. Noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule, which will retain the linker and the amino acid by which it was attached to the antibody.

The selection of linker is target dependent, based on the knowledge of the internalization and degradation of the antibody-target antigen complex, and a preclinical in vitro and in vivo activity comparison of conjugates. Moreover, the choice of a linker is also influenced by which cytotoxin is used, as each molecule has different chemical constraints, and frequently the drug structure lends itself to a specific linker.

ADC Linkers Chemicals

(2-pyridyldithio)-PEG1-hydrazine

Cat. No.: HY-136135

(2-pyridyldithio)-PEG1-hydrazine is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 50 mg, 100 mg

(2-pyridyldithio)-PEG4 acid

Cat. No.: HY-135964

(2-pyridyldithio)-PEG4 acid is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(2-Pyridyldithio)-PEG6 acid

Cat. No.: HY-132086

2-Pyridyldithio-PEG6 acid is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Ac)Phe-Lys(Alloc)-PABC-PNP

Cat. No.: HY-20560

(Ac)Phe-Lys(Alloc)-PABC-PNP is an useful cleavable chemical linker in antibody drug conjugates.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-8-Azido-2-(Fmoc-amino)octanoic acid

Cat. No.: HY-131082

(R)-8-Azido-2-(Fmoc-amino)octanoic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Azetidine-2-carboxylic acid

Cat. No.: HY-W017755

(R)-Azetidine-2-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). (R)-Azetidine-2-carboxylic acid is also a alkyl chain-based PROTAC linker that can be.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

1,6-Bis(mesyloxy)hexane

Cat. No.: HY-138327

16-Bismesyloxyhexane is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Boc-azetidine-3-carboxylic acid

Cat. No.: HY-40141

1-Boc-azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Boc-azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs</sup>.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

1-Boc-azetidine-3-yl-methanol

Cat. No.: HY-40152

1-Boc-azetidine-3-yl-methanol is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Boc-azetidine-3-yl-methanol is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs</sup>.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

1-Cbz-3-Hydroxyazetidine

Cat. No.: HY-77475

1-Cbz-3-Hydroxyazetidine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Cbz-3-Hydroxyazetidine is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

1-Cbz-azetidine-3-carboxylic acid

Cat. No.: HY-W004868

1-Cbz-azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Cbz-azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs</sup>.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

1-N-Boc-3-hydroxyazetidine

Cat. No.: HY-40142

1-N-Boc-3-hydroxyazetidine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-N-Boc-3-hydroxyazetidine is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)

Cat. No.: HY-100138

2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a macrocycle DOTA derivative for tumor pretargeting.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

2-Hydroxyethyl disulfide mono-tosylate

Cat. No.: HY-140125

2-Hydroxyethyl disulfide mono-tosylate is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

20-(tert-Butoxy)-20-oxoicosanoic acid

Cat. No.: HY-W034597

20-(tert-Butoxy)-20-oxoicosanoic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 20-(tert-Butoxy)-20-oxoicosanoic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs<su.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

22-(tert-Butoxy)-22-oxodocosanoic acid

Cat. No.: HY-W046348

22-(tert-Butoxy)-22-oxodocosanoic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 22-(tert-Butoxy)-22-oxodocosanoic acid is also a alkyl chain-based PROTAC linker that can be used in t.

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

4-Methyl-4-(methyldisulfanyl)pentanoic acid

Cat. No.: HY-133408

4-Methyl-4-(methyldisulfanyl)pentanoic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid

Cat. No.: HY-133409

4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-N3Pfp-NHS ester

Cat. No.: HY-126525

4-N3Pfp-NHS ester is a noncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Succinimidyl-oxycarbonyl-α-(2-pyridyldithio)toluene

Cat. No.: HY-133538

4-Succinimidyl-oxycarbonyl-α-(2-pyridyldithio)toluene is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Maleimidovaleric acid

Cat. No.: HY-140987

5-Maleimidovaleric acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

6-Azido-hexylamine

Cat. No.: HY-138387

6-Azido-hexylamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6-Maleimidohexanoic acid N-hydroxysuccinimide ester (EMCS)

Cat. No.: HY-78961

6-Maleimidohexanoic acid N-hydroxysuccinimide ester (EMCS) is a heterobifunctional cross-linking reagent. EMCS is used as a unique and useful reagent for preparation of hapten conjugate and enzyme immunoconjugates.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

6-O-2-Propyn-1-yl-D-galactose

Cat. No.: HY-128930

6-O-2-Propyn-1-yl-D-galactose is a nonclaevable glycolinker for the functionalization of cytotoxic drugs and applications in antibody-drug conjugation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6-Oxohexanoic acid

Cat. No.: HY-141595

6-Oxohexanoic acid is a non-cleavable modified MMAF-C5-COOH linker and can be used in the synthesis of modified MMAF-C5-COOH, a drug-linker conjugate for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AcBut (4-(4-Acetyl-phenoxy)-butyric acid)

Cat. No.: HY-132261

AcBut is a cleavable Ozogamicin linker used in the synthesis of Ozogamicin, a drug-linker conjugate for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Acid-C3-SSPy

Cat. No.: HY-141597

Acid-C3-SSPy is a cleavable DBA-DM4 linker used in the synthesis of DBA-DM4 (HY-128960), a drug-linker conjugate for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acid-PEG1-bis-PEG3-BCN

Cat. No.: HY-136088

Acid-PEG1-bis-PEG3-BCN is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Acid-PEG2-SS-PEG2-acid

Cat. No.: HY-140112

Acid-PEG2-SS-PEG2-acid is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Acid-PEG3-SS-PEG3-acid

Cat. No.: HY-140113

Acid-PEG3-SS-PEG3-acid is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Acid-propionylamino-Val-Cit-OH

Cat. No.: HY-130930

Acid-propionylamino-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

AEEA-AEEA

Cat. No.: HY-W125504

AEEA-AEEA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). AEEA-AEEA is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ala-Ala-Asn-PAB

Cat. No.: HY-129360

Ala-Ala-Asn-PAB is a peptide cleavable **ADC linker** for antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

Ala-CO-amide-C4-Boc

Cat. No.: HY-145367

Ala-CO-amide-C4-Boc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-CH2-PEG3-azide

Cat. No.: HY-130144

Ald-CH2-PEG3-azide is a cleavable 3 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Ald-CH2-PEG3-azide is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-CH2-PEG5-azide

Cat. No.: HY-140634

Ald-CH2-PEG5-azide is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-PEG23-SPDP

Cat. No.: HY-136309

Ald-PEG23-SPDP is a cleavable 23 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALD-PEG4-OPFP

Cat. No.: HY-136127

ALD-PEG4-OPFP is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Ald-Ph-amido-C2-nitrate

Cat. No.: HY-130096

Ald-Ph-amido-C2-nitrate (Example XXIVb) is a thiazolidine derivative, used as a noncleavable **ADC linker**.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Ald-Ph-amido-PEG1-C2-NHS ester

Cat. No.: HY-130106

Ald-Ph-amido-PEG1-C2-NHS ester is a nonclaevable 1-unit PEG linker for antibody-drug-conjugation (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Ald-Ph-amido-PEG1-C2-Pfp ester

Cat. No.: HY-130105

Ald-Ph-amido-PEG1-C2-Pfp ester is a nonclaevable 1-unit PEG linker for antibody-drug-conjugation (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

Ald-Ph-amido-PEG11-C2-NH2

Cat. No.: HY-133546

Ald-Ph-amido-PEG11-C2-NH2 is a non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-Ph-amido-PEG11-NH-Boc

Cat. No.: HY-133572

Ald-Ph-amido-PEG11-NH-Boc is a non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-Ph-amido-PEG2

Cat. No.: HY-130099

Ald-Ph-amido-PEG2 is a noncleavable **ADC linker** for antibody-drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 1 g

Ald-Ph-amido-PEG2-C2-NHS ester

Cat. No.: HY-130104

Ald-Ph-amido-PEG2-C2-NHS ester is a nonclaevable 2-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Ald-Ph-amido-PEG2-C2-Pfp ester

Cat. No.: HY-130103

Ald-Ph-amido-PEG2-C2-Pfp ester is a nonclaevable 2-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Ald-Ph-amido-PEG23-OPSS

Cat. No.: HY-130962

Ald-Ph-amido-PEG23-OPSS is a cleavable 23 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Ald-Ph-amido-PEG3-C-COOH

Cat. No.: HY-130098

Ald-Ph-amido-PEG3-C-COOH is a noncleavable linker used for the antibody-drug conjugate (**ADC**).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Ald-Ph-amido-PEG3-C1-Boc

Cat. No.: HY-130100

Ald-Ph-amido-PEG3-C1-Boc is an ADC linker, which belongs to a polyethylene glycol (PEG) linker.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Ald-Ph-amido-PEG3-C2-Pfp ester

Cat. No.: HY-130102

Ald-Ph-amido-PEG3-C2-Pfp ester is an noncleavable ADC linker, which belongs to a polyethylene glycol (PEG) linker.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Ald-Ph-amido-PEG3-NHS ester

Cat. No.: HY-133579

Ald-Ph-amido-PEG3-NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-Ph-amido-PEG4-C2-acid

Cat. No.: HY-130097

Ald-Ph-amido-PEG4-C2-acid is a noncleavable linker used for the antibody-drug conjugate (**ADC**).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Ald-Ph-amido-PEG4-C2-NHS ester

Cat. No.: HY-130101

Ald-Ph-amido-PEG4-C2-NHS ester is a nonclaevable 4-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-Ph-amido-PEG4-propargyl

(Ald-benzyl-amide-PEG4-propargyl)

Cat. No.: HY-133426

Ald-Ph-amido-PEG4-propargyl is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ald-Ph-NHS ester

Cat. No.: HY-130107

Ald-Ph-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Ald-Ph-PEG4-bis-PEG3-methyltetrazine

Cat. No.: HY-130974

Ald-Ph-PEG4-bis-PEG3-methyltetrazine is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Ald-Ph-PEG4-bis-PEG3-N3

Cat. No.: HY-130969

Ald-Ph-PEG4-bis-PEG3-N3 is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Ald-Ph-PEG4-bis-PEG4-propargyl

Cat. No.: HY-130967

Ald-Ph-PEG4-bis-PEG4-propargyl is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Alkyne-PEG4-SS-PEG4-alkyne

Cat. No.: HY-135970

Alkyne-PEG4-SS-PEG4-alkyne is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aloc-D-Ala-Phe-Lys(Aloc)-PAB-PNP

Cat. No.: HY-129351

Aloc-D-Ala-Phe-Lys(Aloc)-PAB-PNP is a cleavable **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

AMAS

Cat. No.: HY-128925

AMAS is a nonclaevable heterobifunctional crosslinker with NHS ester and maleimide groups that allows covalent conjugation of amine- and sulfhydryl-containing molecules.



Purity: ≥97.0%
Clinical Data:
Size: 10 mg, 25 mg, 50 mg

Amino-bis-PEG3-BCN

Cat. No.: HY-136085

Amino-bis-PEG3-BCN is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amino-bis-PEG3-DBCO

Cat. No.: HY-130972

Amino-bis-PEG3-DBCO is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amino-bis-PEG3-TCO

Cat. No.: HY-130955

Amino-bis-PEG3-TCO is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-ethyl-SS-PEG3-NHBoc

Cat. No.: HY-140099

Amino-ethyl-SS-PEG3-NHBoc is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amino-PEG10-OH

Cat. No.: HY-120761

Amino-PEG10-OH is non-cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG10-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-PEG11-OH

Cat. No.: HY-130298

Amino-PEG11-OH is non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG11-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-PEG2-C2-acid

Cat. No.: HY-W040168

Amino-PEG2-C2-acid is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG2-C2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Amino-PEG3-C2-acid

Cat. No.: HY-W040165

Amino-PEG3-C2-acid is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG3-C2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Amino-PEG3-SS-acid

Cat. No.: HY-135974

Amino-PEG3-SS-acid is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-PEG4-alcohol

Cat. No.: HY-W008005

Amino-PEG4-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Amino-PEG4-alcohol is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Amino-PEG4-bis-PEG3-methyltetrazine

Cat. No.: HY-130970

Amino-PEG4-bis-PEG3-methyltetrazine is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amino-PEG4-bis-PEG3-N3

Cat. No.: HY-136090

Amino-PEG4-bis-PEG3-N3 is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amino-PEG4-bis-PEG3-propargyl

Cat. No.: HY-130968

Amino-PEG4-bis-PEG3-propargyl is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amino-PEG4-CH2COOH

Cat. No.: HY-130524

Amino-PEG4-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Amino-PEG4-CH2COOH is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-PEG4-Val-Cit-PAB-MMAE

Cat. No.: HY-141154

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Amino-PEG5-C2-acid

Cat. No.: HY-115384

Amino-PEG5-C2-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Amino-PEG5-C2-acid is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-PEG6-alcohol

Cat. No.: HY-126942

Amino-PEG6-alcohol is a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG6-alcohol is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-PEG6-amido-bis-PEG5-N3

Cat. No.: HY-130957

Amino-PEG6-amido-bis-PEG5-N3 is a cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amino-PEG8-Boc

Cat. No.: HY-W019799

Amino-PEG8-Boc is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG8-Boc is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Amino-PEG9-acid

Cat. No.: HY-130166

Amino-PEG9-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.
Amino-PEG9-acid is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Amino-SS-PEG12-acid

Cat. No.: HY-140097

Amino-SS-PEG12-acid is a cleavable 12 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amino-Tri-(carboxyethoxymethyl)-methane

Cat. No.: HY-117519

Amino-Tri-(carboxyethoxymethyl)-methane is a cleavable PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).
Amino-Tri-(carboxyethoxymethyl)-methan is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminoethyl-SS-ethylalcohol

Cat. No.: HY-117409

Aminoethyl-SS-ethylalcohol is a glutathione cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminoethyl-SS-propionic acid

Cat. No.: HY-140096

Aminoethyl-SS-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.03%
Clinical Data:
Size: 10 mg, 25 mg, 50 mg

Aminooxy-amido-PEG4-propargyl

Cat. No.: HY-133435

Aminooxy-amido-PEG4-propargyl is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Aminooxy-PEG2-alcohol

Cat. No.: HY-126951

Aminooxy-PEG2-alcohol is a non-cleavable 2 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).
Aminooxy-PEG2-alcohol is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxy-PEG2-azide

Cat. No.: HY-113931

Aminooxy-PEG2-azide is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.
Aminooxy-PEG2-azide is also a non-cleavable 2 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxy-PEG2-BCN

Cat. No.: HY-145593

Aminooxy-PEG2-BCN is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxy-PEG2-bis-PEG3-BCN

Cat. No.: HY-136089

Aminooxy-PEG2-bis-PEG3-BCN is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxy-PEG3-azide

Cat. No.: HY-126949

Aminooxy-PEG3-azide is a non-cleavable 3 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Aminooxy-C2-PEG3-azide is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxy-PEG4-alcohol

Cat. No.: HY-124123

Aminooxy-PEG4-alcohol is a non-cleavable 4 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Aminooxy-PEG4-alcohol is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminoxyacetamide-PEG3-azide

Cat. No.: HY-133434

Aminoxyacetamide-PEG3-azide is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APN-PEG36-tetrazine

Cat. No.: HY-139859

APN-PEG36-tetrazine is an analogue of APN-PEG4-tetrazine. APN-PEG4-tetrazine is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: 96.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

APN-PEG4-Amine hydrochloride

Cat. No.: HY-130939

APN-PEG4-Amine (hydrochloride) is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APN-PEG4-BCN

Cat. No.: HY-136044

APN-PEG4-BCN is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APN-PEG4-DBCO

Cat. No.: HY-136049

APN-PEG4-DBCO is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

APN-PEG4-tetrazine

Cat. No.: HY-136045

APN-PEG4-tetrazine is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azetidin-3-ol hydrochloride

Cat. No.: HY-40144

Azetidin-3-ol hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetidin-3-ol hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthes PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Azetidine-3-carboxylic acid

Cat. No.: HY-Y0530

Azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[12].



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azide-C2-Azide

Cat. No.: HY-138535

Azide-C2-Azide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azide-C2-SS-C2-biotin

Cat. No.: HY-140127

Azide-C2-SS-C2-biotin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 25 mg, 50 mg, 100 mg

Azide-PEG1-Val-Cit-PABC-OH

Cat. No.: HY-136137

Azide-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azide-PEG3-Tos

Cat. No.: HY-140004

Azide-PEG3-Tos is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs. Azide-PEG3-Tos is also a non-cleavable 3 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azide-PEG5-Tos

Cat. No.: HY-140352

Azide-PEG5-Tos is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azido-C2-SS-PEG2-C2-acid

Cat. No.: HY-140101

Azido-C2-SS-PEG2-C2-acid is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azido-C6-OH

Cat. No.: HY-138521

Azido-C6-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG1-Val-Cit-OH

Cat. No.: HY-136034

Azido-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG1-Val-Cit-PABC-PNP

Cat. No.: HY-136105

Azido-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azido-PEG2-C2-amine

(N3-PEG2-CH2CH2NH2)

Cat. No.: HY-140213

Azido-PEG2-C2-amine (N3-PEG2-CH2CH2NH2) is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs. Azido-PEG2-C2-amine is also a non-cleavable 2 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Azido-PEG3-maleimide

Cat. No.: HY-140811

Azido-PEG3-maleimide is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs. Azido-PEG3-maleimide is also a cleavable 3 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg

Azido-PEG3-SS-NHS

Cat. No.: HY-135966

Azido-PEG3-SS-NHS is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 25 mg, 50 mg

Azido-PEG3-SSPy

Cat. No.: HY-136038

Azido-PEG3-SSPy is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG3-Val-Cit-PAB-OH

Cat. No.: HY-140148

Azido-PEG3-Val-Cit-PAB-OH is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azido-PEG3-Val-Cit-PAB-PNP

Cat. No.: HY-140150

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Azido-PEG4-C2-acid

Cat. No.: HY-130653

Azido-PEG4-C2-acid a PEG-based **PROTAC** linker can be used in the synthesis of vRucaparib-TP4. Azido-PEG4-C2-acid is also a non-cleavable 4 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Azido-PEG4-CH2-Boc

Cat. No.: HY-42618

Azido-PEG4-CH2-Boc is a cleavable 4 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-CH2-Boc is also a PEG- and Alkyl/ether-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Azido-PEG4-Val-Cit-PAB-OH

Cat. No.: HY-140149

Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Azido-PEG5-acid

Cat. No.: HY-130572

Azido-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs, such as the conjugate CPT-APO (CPT: Camptothecin (HY-16560)). Azido-PEG5-acid is a non-cleavable 5 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG5-Ala-Ala-Asn-PAB

Cat. No.: HY-141150

Azido-PEG5-Ala-Ala-Asn-PAB is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azido-PEG5-alcohol

Cat. No.: HY-130211

Azido-PEG5-alcohol is a non-cleavable 5 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG5-alcohol is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG5-CH2CO2H

Cat. No.: HY-130194

Azido-PEG5-CH2CO2H is a cleavable 5 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG5-CH2CO2H is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: 99.60%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Azido-PEG6-alcohol

Cat. No.: HY-130537

Azido-PEG6-alcohol is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs. Azido-PEG6-alcohol is also a non-cleavable 6 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG6-amine

Cat. No.: HY-140215

Azido-PEG6-amine is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs. Azido-PEG6-amine is also a non-cleavable 6 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg, 500 mg

Azido-PEG6-NHS ester

Cat. No.: HY-130474

Azido-PEG6-NHS ester is a cleavable 6 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG6-NHS ester is also a PEG- and Alkyl/ether based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: 98.85%
Clinical Data: No Development Reported
Size: 100 mg

Azido-PEG7-amine

Cat. No.: HY-130324

Azido-PEG7-amine is a non-cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG7-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Azido-PEG8-acid

Cat. No.: HY-140454

Azido-PEG8-acid is a non-cleavable 8 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG8-acid is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Azido-PEG8-NHS ester

Cat. No.: HY-130184

Azido-PEG8-NHS ester is a cleavable 8 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG8-NHS ester is also a PEG- and Alkyl/ether-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg

Azido-PEG9-acid

Cat. No.: HY-130475

Azido-PEG9-acid is a non-cleavable 9 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG9-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG9-amine

Cat. No.: HY-130169

Azido-PEG9-amine is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG9-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azidoethyl-SS-ethylamine

Cat. No.: HY-140104

Azidoethyl-SS-ethylamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azidoethyl-SS-ethylazide

Cat. No.: HY-140105

Azidoethyl-SS-ethylazide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azidoethyl-SS-propionic acid

Cat. No.: HY-140100

Azidoethyl-SS-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Azidoethyl-SS-propionic NHS ester

Cat. No.: HY-140102

Azidoethyl-SS-propionic NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCN-PEG1-Val-Cit-OH

Cat. No.: HY-130922

BCN-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

BCN-PEG1-Val-Cit-PABC-OH

Cat. No.: HY-130923

BCN-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCN-PEG3-Biotin

Cat. No.: HY-130924

BCN-PEG3-Biotin is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data:
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BCN-PEG3-oxyamine

Cat. No.: HY-130926

BCN-PEG3-oxyamine is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

BCN-PEG3-Val-Cit

Cat. No.: HY-140151

BCN-PEG3-Val-Cit is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
BCN-PEG3-Val-Cit is also a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCN-PEG3-VC-PFP ester

Cat. No.: HY-140152

BCN-PEG3-VC-PFP ester is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCN-PEG4-acid

Cat. No.: HY-135971

BCN-PEG4-acid is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 250 mg

BCN-PEG4-HyNic

Cat. No.: HY-136061

BCN-PEG4-HyNic is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

BCN-PEG4-OH

Cat. No.: HY-130925

BCN-PEG4-OH is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCN-PEG4-Ts

Cat. No.: HY-130927

BCN-PEG4-Ts is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCN-SS-amine

Cat. No.: HY-135972

BCN-SS-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

BCN-SS-NHS

Cat. No.: HY-135973

BCN-SS-NHS is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg

BCOT-PEF3-OPFP

Cat. No.: HY-136125

BCOT-PEF3-OPFP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

BDP FL DBCO

Cat. No.: HY-140296

BDP FL DBCO is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biotin-C4-amide-C5-NH2

Cat. No.: HY-W096148

Biotin-C4-amide-C5-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biotin-PEG1-azide

Cat. No.: HY-W096133

Biotin-PEG1-azide is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biotin-PEG1-NH2

Cat. No.: HY-W096135

Biotin-PEG1-NH2 is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biotin-PEG2-acid

Cat. No.: HY-126958

Biotin-PEG2-acid is a non-cleavable 2 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Biotin-PEG2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: 96.14%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Biotin-PEG2-methyl ethanethioate

Cat. No.: HY-138508

Biotin-PEG2-methyl ethanethioate is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biotin-PEG3-aldehyde

Cat. No.: HY-136051

Biotin-PEG3-aldehyde is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biotin-PEG3-SS-azide

Cat. No.: HY-140944

Biotin-PEG3-SS-azide is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥98.0%
Clinical Data:
Size: 5 mg

Biotin-PEG4-Dde-TAMRA-PEG3-Azide

Cat. No.: HY-141091

Biotin-PEG4-Dde-TAMRA-PEG3-Azide is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Biotin-PEG4-PFP ester

Cat. No.: HY-138488

Biotin-PEG4-PFP ester is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biotin-PEG4-SS-azide

Cat. No.: HY-139107

Biotin-PEG4-SS-azide is a cleavable, biotin-labeled, ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

Biotin-sar-oh

Cat. No.: HY-W096127

Biotin-sar-oh is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-(PEG6-acid)-SS

Cat. No.: HY-140115

Bis-(PEG6-acid)-SS is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Bis-PEG1-NHS ester

Cat. No.: HY-130089

Bis-PEG1-NHS ester is a nonclaevable 1-unit PEG linker for antibody-drug-conjugation (ADC).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Bis-PEG1-PFP ester

Cat. No.: HY-112561

Bis-PEG1-PFP ester is a non-cleavable (1 unit PEG) ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG10-NHS ester

Cat. No.: HY-130824

Bis-PEG10-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG10-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG13-NHS ester

Cat. No.: HY-130825

Bis-PEG13-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG13-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG17-NHS ester

Cat. No.: HY-130826

Bis-PEG17-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG17-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

bis-PEG2-endo-BCN

Cat. No.: HY-140078

bis-PEG2-endo-BCN is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: 98.10%
Clinical Data:
Size: 50 mg

Bis-PEG2-PFP ester

Cat. No.: HY-112560

Bis-PEG2-PFP ester is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Bis-PEG2-PFP ester is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG21-NHS ester

Cat. No.: HY-130827

Bis-PEG21-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG21-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG25-NHS ester

Cat. No.: HY-130828

Bis-PEG25-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG25-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG3-NHS ester

Cat. No.: HY-130087

Bis-PEG3-NHS ester is a nonclaevable 3-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG5-NHS ester

Cat. No.: HY-126889

Bis-PEG5-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG5-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG6-NHS ester

Cat. No.: HY-130410

Bis-PEG6-NHS ester is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.
Bis-PEG6-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Bis-PEG7-acid

Cat. No.: HY-126892

Bis-PEG7-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.
Bis-PEG6-propionic acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG7-NHS ester

Cat. No.: HY-126890

Bis-PEG7-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG7-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Bis-PEG8-acid

Cat. No.: HY-126893

Bis-PEG8-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG8-acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG9-acid

Cat. No.: HY-126894

Bis-PEG9-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.
Bis-PEG9-acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG9-NHS ester

Cat. No.: HY-117009

Bis-PEG9-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Bis-PEG9-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Bis-SS-C3-NHS ester

Cat. No.: HY-133584

Bis-SS-C3-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-SS-C3-sulfo-NHS ester

Cat. No.: HY-133585

Bis-SS-C3-sulfo-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-sulfone-PEG3-Azide

Cat. No.: HY-138745

Bis-sulfone-PEG3-Azide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Bis-Tos-(2-hydroxyethyl disulfide)

Cat. No.: HY-140126

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG2-NHS ester

Cat. No.: HY-130088

Bis-PEG2-NHS ester is a nonclaevable 2-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Bis-PEG4-NHS ester

Cat. No.: HY-130086

Bis-PEG4-NHS ester is a nonclaevable 4-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMPS

Cat. No.: HY-42146

BMPS is a nonclaevable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.93%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

BnO-PEG6-OH

Cat. No.: HY-W042654

BnO-PEG6-OH is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). BnO-PEG6-OH is also a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 100 mg

Boc-amino-PEG3-SS-acid

Cat. No.: HY-136037

Boc-amino-PEG3-SS-acid is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Boc-amino-PEG3-SSPy

Cat. No.: HY-136041

Boc-amino-PEG3-SSPy is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Boc-aminooxy-amide-PEG4-propargyl

Cat. No.: HY-133436

Boc-aminooxy-amide-PEG4-propargyl is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Boc-aminooxy-ethyl-SS-propanol

Cat. No.: HY-140117

Boc-aminooxy-ethyl-SS-propanol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Boc-Aminooxy-PEG2-bromide

Cat. No.: HY-135962

Boc-Aminooxy-PEG2-bromide is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Boc-C14-COOH

Cat. No.: HY-W034599

Boc-C14-COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-C14-COOH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-C16-COOH

Cat. No.: HY-W045598

Boc-C16-COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-C16-COOH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs<su.

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid

Cat. No.: HY-108379

Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-Cystamine

Cat. No.: HY-140098

Boc-Cystamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Boc-Dap-NE

Cat. No.: HY-78931

Boc-Dap-NE, a dipeptide, is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Boc-Gly-Gly-Phe-Gly-OH

Cat. No.: HY-P1449

Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate **(ADC)**.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mg

Boc-Gly-Gly-Phe-Gly-OH TFA

Cat. No.: HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate **(ADC)**.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mg

Boc-gly-PEG3-endo-BCN

Cat. No.: HY-140081

Boc-gly-PEG3-endo-BCN is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Boc-gly-PEG3-endo-BCN is also a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-Hyp-OH

Cat. No.: HY-I0781

Boc-Hyp-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-Hyp-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs</s.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

Boc-Hyp-OMe

Cat. No.: HY-65039

Boc-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

Boc-NH-C6-Br

Cat. No.: HY-W011561

Boc-NH-C6-Br is a non-cleavable linker used for antibody-drug conjugates (**ADC**).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg

Boc-NH-ethyl-SS-propionic acid

Cat. No.: HY-140116

Boc-NH-ethyl-SS-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 100 mg, 250 mg, 500 mg

Boc-NH-PEG1-CH2CH2COOH

Cat. No.: HY-120775

Boc-NH-PEG1-CH2CH2COOH is a cleavable (1 unit PEG) ADC linker and also a **PEG**- and **Alkyl/ether**-based **PROTAC linker** can be used in the synthesis of antibody-drug conjugates (ADCs) or PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA

Cat. No.: HY-126677

Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA is a double claevable 3-unit and 4-unit PEG linker for antibody-drug-conjugation (ADC). Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA also is a PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-NH-PEG4-CH2CH2COOH

Cat. No.: HY-W040132

Boc-NH-PEG4-CH2CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC. Boc-NH-PEG4-CH2CH2COOH is also a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Boc-NH-PEG4-CH2CH2NH2

Cat. No.: HY-W008352

Boc-NH-PEG4-CH2CH2NH2 a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-NH-PEG4-CH2CH2NH2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg

Boc-NH-PEG4-CH2COOH

Cat. No.: HY-42640

Boc-NH-PEG4-CH2COOH is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC). Boc-NH-PEG4-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Boc-NH-PEG6-CH2CH2COOH

Cat. No.: HY-W040244

Boc-NH-PEG6-CH2CH2COOH is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC). Boc-NH-PEG6-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-NMe-Val-Val-Dil-Dap-OH

Cat. No.: HY-130956

Boc-NMe-Val-Val-Dil-Dap-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-Phe-(Alloc)Lys-PAB-PNP

Cat. No.: HY-129353

Boc-Phe-(Alloc)Lys-PAB-PNP is a used as a cleavable linker for antibody-drug conjugates (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

Boc-trans-D-Hyp-OMe

Cat. No.: HY-W017882

Boc-trans-D-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-trans-D-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Boc-Val-Ala-PAB-PNP

Cat. No.: HY-130932

Boc-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Boc-Val-Cit-OH

Cat. No.: HY-W038702

Boc-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 1 g

Boc-Val-Cit-PAB

Cat. No.: HY-141141

Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.99%
Clinical Data:
Size: 25 mg, 50 mg, 100 mg

Boc-Val-Cit-PAB-PNP

Cat. No.: HY-141142

Boc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Boc-Val-Dil-Dap-OH

Cat. No.: HY-130961

Boc-Val-Dil-Dap-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 100 mg

Boc-Val-Dil-Dap-Phe-OMe

Cat. No.: HY-130975

Boc-Val-Dil-Dap-Phe-OMe is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bocaminooxyacetamide-PEG2-Azido

Cat. No.: HY-136099

Bocaminooxyacetamide-PEG2-Azido is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Bocaminooxyacetamide-PEG3-alkyne

Cat. No.: HY-136101

Bocaminooxyacetamide-PEG3-alkyne is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Br-PEG4-C2-Boc

Cat. No.: HY-130315

Br-PEG4-C2-Boc is a cleavable 4 unit **PEG ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Bromo-PEG2-C2-azide

Cat. No.: HY-130485

Bromo-PEG2-C2-azide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Bromo-PEG2-C2-azide is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Bromoacetamido-PEG4-acid

Cat. No.: HY-141382

Bromoacetamido-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Bromoacetamido-PEG4-acid is also a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BS2G Crosslinker disodium

Cat. No.: HY-130547

BS2G Crosslinker (disodium) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BS3 Crosslinker

Cat. No.: HY-124329

BS3 Crosslinker is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BS3 Crosslinker disodium

Cat. No.: HY-124329A

BS3 Crosslinker disodium is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Cbz-Phe-(Alloc)Lys-PAB-PNP

Cat. No.: HY-129352

Cbz-Phe-(Alloc)Lys-PAB-PNP is an cleavable linker for antibody-drug conjugates (**ADC**) design.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

cis-4-Hydroxy-D-proline hydrochloride

Cat. No.: HY-76104

cis-4-Hydroxy-D-proline hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). cis-4-Hydroxy-D-proline hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

cis-4-Hydroxy-L-proline hydrochloride

Cat. No.: HY-W019213

cis-4-Hydroxy-L-proline hydrochloride is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). cis-4-Hydroxy-L-proline hydrochloride is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

CL2 Linker

Cat. No.: HY-128947

CL2 Linker is a cleavable**ADC** linker. CL2-SN-38 and CL2A-SN-38 are equivalent in drug substitution (~6), cell binding (K_d ~1.2 nM), cytotoxicity (IC_{50} ~2.2 nM), and serum stability in vitro ($t_{1/2}$ ~20 hours).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL2A

Cat. No.: HY-128945

CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cyclooctyne-O-amido-PEG2-PFP ester

Cat. No.: HY-133573

Cyclooctyne-O-amido-PEG2-PFP ester is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclooctyne-O-amido-PEG3-PFP ester

Cat. No.: HY-133575

Cyclooctyne-O-amido-PEG3-PFP ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclooctyne-O-amido-PEG4-PFP ester

Cat. No.: HY-133576

Cyclooctyne-O-amido-PEG4-PFP ester is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclooctyne-O-NHS ester

Cat. No.: HY-126517

Cyclooctyne-O-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg, 100 mg, 500 mg, 1 g

Cyclooctyne-O-PFP ester

Cat. No.: HY-126518

Cyclooctyne-O-PFP ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 95.05%
Clinical Data: No Development Reported
Size: 100 mg, 1 g

D-Proline, 4-hydroxy-, methyl ester hydrochloride

Cat. No.: HY-76105

D-Proline, 4-hydroxy-, methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-(PEG2-Val-Cit-PAB)2

Cat. No.: HY-126676

DBCO-(PEG2-Val-Cit-PAB)2 is a dual cleavable **ADC linker** for antibody-drug conjugates (ADCs). DBCO-(PEG2-Val-Cit-PAB)2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-acid

Cat. No.: HY-42972

DBCO-acid is a cleavable ADC linker used in the synthesis of ADC linker DBCO-NHS ester (HY-115524 and HY-115545), and drug-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690).



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DBCO-amine

Cat. No.: HY-W000423

DBCO-amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.86%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

DBCO-C3-Acid

Cat. No.: HY-120903

DBCO-C3-Acid is a Click Chemistry intermediate used in the synthesis of antibody-drug conjugate (ADC) linker.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

DBCO-CONH-S-S-NHS ester

Cat. No.: HY-133413

DBCO-CONH-S-S-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 95.04%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

DBCO-Maleimide

Cat. No.: HY-116270

DBCO-Maleimide is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 96.41%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 250 mg

DBCO-N-bis(PEG4-NHS ester)

Cat. No.: HY-145090

DBCO-N-bis(PEG4-NHS ester) is a PEG linker which contains two PEG4-NHS ester and a DBCO group. DBCO-N-bis(PEG4-NHS ester) is useful for protein modification or labeling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-NHCO-PEG4-acid

Cat. No.: HY-125541

DBCO-Amide-PEG5-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. DBCO-Amide-PEG5-acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-NHCO-PEG4-amine

Cat. No.: HY-124386

DBCO-NHCO-PEG4-amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-amine is a cleavable **ADC linker** used to conjugate MMAE (HY-15162) and antibody (e.g.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-NHCO-PEG4-NH-Boc

Cat. No.: HY-126884

DBCO-NHCO-PEG4-NH-Boc is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-NH-Boc is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-NHCO-PEG4-NHS ester

Cat. No.: HY-111456

DBCO-NHCO-PEG4-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. DBCO-NHCO-PEG4-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-NHCO-S-S-NHS ester

Cat. No.: HY-133412

DBCO-NHCO-S-S-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-NHS ester

Cat. No.: HY-42973

DBCO-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

DBCO-NHS ester 2

Cat. No.: HY-115524

DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-NHS ester 3

Cat. No.: HY-115545

DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG3 acetic-EVCit-PAB

Cat. No.: HY-136096

DBCO-PEG3 acetic-EVCit-PAB is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG3-oxyamine

Cat. No.: HY-133429

DBCO-PEG3-oxyamine is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG3-propionic EVCit-PAB

Cat. No.: HY-136141

DBCO-PEG3-propionic EVCit-PAB is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG3-SS-NHS ester

Cat. No.: HY-133431

DBCO-PEG3-SS-NHS ester is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥90.0%
Clinical Data:
Size: 25 mg

DBCO-PEG3-TCO

Cat. No.: HY-133428

DBCO-PEG3-TCO is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

DBCO-PEG4-acetic-Val-Cit-PAB

Cat. No.: HY-136098

DBCO-PEG4-acetic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

DBCO-PEG4-alkyne

Cat. No.: HY-133430

DBCO-PEG4-alkyne is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

DBCO-PEG4-amine

Cat. No.: HY-130435

DBCO-PEG4-amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.
DBCO-PEG4-amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

DBCO-PEG4-DBCO

Cat. No.: HY-130346

DBCO-PEG4-DBCO is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. DBCO-PEG4-DBCO is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-HyNic

Cat. No.: HY-136067

DBCO-PEG4-HyNic is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 25 mg, 50 mg, 100 mg

DBCO-PEG4-Maleimide

Cat. No.: HY-120770

DBCO-PEG4-Maleimide is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: 98.02%
Clinical Data: No Development Reported
Size: 100 mg

DBCO-PEG4-Propionic-Val-Cit-PAB

Cat. No.: HY-136103

DBCO-PEG4-Propionic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

DBCO-PEG4-SS-TCO

Cat. No.: HY-133432

DBCO-PEG4-SS-TCO is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

DBCO-PEG5-NHS ester

Cat. No.: HY-126885

DBCO-PEG5-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. DBCO-PEG5-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

DBCO-S-S-acid

Cat. No.: HY-138506

DBCO-S-S-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-SS-aldehyde

Cat. No.: HY-135977

DBCO-SS-aldehyde is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

DBCO-SS-amine

Cat. No.: HY-135978

DBCO-SS-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-SS-PEG4-Biotin

Cat. No.: HY-135979

DBCO-SS-PEG4-Biotin is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

DBCO-Sulfo-Link-biotin

Cat. No.: HY-130810

DBCO-Sulfo-Link-biotin is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

DBCO-Sulfo-NHS ester sodium

Cat. No.: HY-123687

DBCO-Sulfo-NHS ester sodium is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

DBCO-Val-Cit-OH

Cat. No.: HY-130935

DBCO-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-Val-Cit-PABC-OH

Cat. No.: HY-130936

DBCO-Val-Cit-PABC-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-Val-Cit-PABC-PNP

Cat. No.: HY-130937

DBCO-Val-Cit-PABC-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

DBCO-C6-acid

Cat. No.: HY-121805

DBCO-C6-acid is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). DBCO-C6-acid can be used in the synthesis of carmaphycin analogues.



Purity: 95.38%
Clinical Data: No Development Reported
Size: 25 mg

Diazo Biotin-PEG3-DBCO

Cat. No.: HY-140930

Diazo Biotin-PEG3-DBCO is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Dimethylamine-SPDB

Cat. No.: HY-133542

Dimethylamine-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM21

Cat. No.: HY-139441

DM21 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DMAC-PDB

Cat. No.: HY-126531

DMAC-PDB is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

DMAC-SPDB

Cat. No.: HY-133550

DMAC-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DMAC-SPDB-sulfo

Cat. No.: HY-131084

DMAC-SPDB-sulfo is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DMAC-SPP

Cat. No.: HY-130111

DMAC-SPP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Docosanedioic acid

Cat. No.: HY-W034918

Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

DOTA-NHS-ester

Cat. No.: HY-128890

DOTA-NHS-ester is a **linker** for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors.



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 100 mg

DSG Crosslinker

Cat. No.: HY-114697

DSG Crosslinker is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DSP Crosslinker

Cat. No.: HY-118759

DSP Crosslinker is a cleavable **ADC linker**, used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.73%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

DSS Crosslinker

Cat. No.: HY-W019543

DSS Crosslinker is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

DTSSP Crosslinker

Cat. No.: HY-126349

DTSSP Crosslinker is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

EC089

Cat. No.: HY-128940

EC089 is a cleavable linker used in conjugates of tubulysins and folates, and extracted from patent WO2011069116A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eicosanedioic acid

Cat. No.: HY-W034595

Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eicosanedioic acid-d4

Cat. No.: HY-W034595S

Eicosanedioic acid-d4 is the deuterium labeled Eicosanedioic acid. Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

endo-BCN-PEG4-Val-Cit-PAB-MMAE

Cat. No.: HY-141155

endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ethyl azetidine-3-carboxylate hydrochloride

Cat. No.: HY-W052600

Ethyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Ethyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[c/s].



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

Fluorescein-DBCO

Cat. No.: HY-126851

Fluorescein-DBCO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-3VVD-OH

Cat. No.: HY-78921

Fmoc-3VVD-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Fmoc-8-amino-3,6-dioxaoctanoic acid

(Fmoc-NH-PEG2-CH2COOH)

Cat. No.: HY-W007713

Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-NH-PEG2-CH2COOH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-8-amino-3,6-dioxaoctanoic acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Fmoc-Ala-Ala-Asn(Trt)-OH

Cat. No.: HY-130933

Fmoc-Ala-Ala-Asn(Trt)-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 5 mg, 10 mg

Fmoc-Ala-Ala-Asn-PABC-PNP

Cat. No.: HY-129361

Fmoc-Ala-Ala-Asn-PABC-PNP is a peptide cleavable ADC linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Fmoc-aminooxy-PEG2-NH2

Cat. No.: HY-131955

Fmoc-aminooxy-PEG2-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 95.05%
Clinical Data: No Development Reported
Size: 250 mg, 1 g

Fmoc-Asp-NH2

Cat. No.: HY-135418

Fmoc-Asp-NH2 is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 2 g

Fmoc-azetidine-3-carboxylic acid

Cat. No.: HY-W011277

Fmoc-azetidine-3-carboxylic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Fmoc-D-Trp(Boc)-OH

Cat. No.: HY-79129

Fmoc-D-Trp(Boc)-OH is a cleavable ADC linker that used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 g

Fmoc-D-Val-Cit-PAB

Cat. No.: HY-19318B

Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Fmoc-D-Val-D-Cit-PAB

Cat. No.: HY-19318C

Fmoc-D-Val-D-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Fmoc-Glu-(Boc)-Val-Cit-PAB-PNP

Cat. No.: HY-136154

Fmoc-Glu-(Boc)-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Fmoc-Gly-Gly-D-Phe-OH

Cat. No.: HY-131833A

Fmoc-Gly-Gly-D-Phe-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Gly-Gly-D-Phe-OH is the D-isomer of Fmoc-Gly-Gly-Phe-OH (HY-131833).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg

Fmoc-Gly-Gly-D-Phe-OtBu

Cat. No.: HY-44234A

Fmoc-Gly-Gly-D-Phe-OtBu is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Gly-Gly-D-Phe-OtBu is the R-isomer of Fmoc-Gly-Gly-Phe-OtBu (HY-44234).



Purity: 98.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fmoc-Gly-Gly-OH

Cat. No.: HY-W023121

Fmoc-Gly-Gly-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.81%
Clinical Data: No Development Reported
Size: 500 mg

Fmoc-Gly-Gly-Phe-OH

Cat. No.: HY-131833

Fmoc-Gly-Gly-Phe-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.30%
Clinical Data: No Development Reported
Size: 500 mg

Fmoc-Gly-Gly-Phe-OtBu

Cat. No.: HY-44234

Fmoc-Gly-Gly-Phe-OtBu is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fmoc-Gly3-Val-Cit-PAB

Cat. No.: HY-136106

Fmoc-Gly3-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Fmoc-Gly3-Val-Cit-PAB-PNP

Cat. No.: HY-136108

Fmoc-Gly3-Val-Cit-PAB-PNP is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-Hyp(Bom)-OH

Cat. No.: HY-79125

Fmoc-Hyp(Bom)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Hyp(Bom)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs<.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-Lys(Pal-Glu-OtBu)-OH

Cat. No.: HY-W045822

Fmoc-Lys(Pal-Glu-OtBu)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Lys(Pal-Glu-OtBu)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-Lys-OH hydrochloride

Cat. No.: HY-W010975

Fmoc-Lys-OH hydrochloride is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Lys-OH hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 g, 5 g

Fmoc-N-bis-PEG3-NH-Boc

Cat. No.: HY-130941

Fmoc-N-bis-PEG3-NH-Boc is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-N-methyl-PEG3-CH2CH2COOH

Cat. No.: HY-W035378

Fmoc-N-methyl-PEG3-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-N-methyl-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-Azide-PEG4-L-Lysine-PFP ester

Cat. No.: HY-136155

Fmoc-NH-Azide-PEG4-L-Lysine-PFP ester is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-NH-ethyl-SS-propionic acid

Cat. No.: HY-140118

Fmoc-NH-ethyl-SS-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-ethyl-SS-propionic NHS ester

Cat. No.: HY-140119

Fmoc-NH-ethyl-SS-propionic NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-NH-PEG1-CH2COOH

Cat. No.: HY-W055861

Fmoc-NH-PEG1-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG1-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 500 mg

Fmoc-NH-PEG2-CH2CH2COOH

Cat. No.: HY-W040238

Fmoc-NH-PEG2-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG2-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: 95.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Fmoc-NH-PEG3-CH2CH2COOH

Cat. No.: HY-W040231

Fmoc-NH-PEG3-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Fmoc-NH-PEG4-CH2CH2COOH

(Fmoc-15-amino-4,7,10,13-tetraoxapentadecanoic acid) Cat. No.: HY-W000434

Fmoc-NH-PEG4-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG4-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 100 mg

Fmoc-NH-PEG4-CH2COOH

Cat. No.: HY-130175

Fmoc-NH-PEG4-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG4-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Fmoc-NH-PEG5-CH2COOH

Cat. No.: HY-133062

Fmoc-NH-PEG5-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG5-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-PEG6-CH2CH2COOH

Cat. No.: HY-W040246

Fmoc-NH-PEG6-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: 98.86%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

Fmoc-NH-PEG6-CH2COOH

Cat. No.: HY-130364

Fmoc-NH-PEG6-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG6-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-PEG8-CH2CH2COOH

Cat. No.: HY-W040135

Fmoc-NH-PEG8-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-NH-PEG8-CH2COOH

Cat. No.: HY-133063

Fmoc-NH-PEG8-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG8-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Fmoc-NH-PEG9-CH2CH2COOH

Cat. No.: HY-130167

Fmoc-NH-PEG9-CH2CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG9-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-PEA

Cat. No.: HY-128929

Fmoc-PEA (Example 1-2) is a used as a cleavable linker for antibody-drug conjugates (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB

Cat. No.: HY-141151

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-PEG4-Ala-Ala-Asn-PAB

Cat. No.: HY-141149

Fmoc-PEG4-Ala-Ala-Asn-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-Phe-Lys(Boc)-PAB-PNP

Cat. No.: HY-114430

Fmoc-Phe-Lys(Boc)-PAB-PNP is a cleavable **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.67%
Clinical Data: No Development Reported
Size: 50 mg

Fmoc-Phe-Lys(Trt)-PAB

Cat. No.: HY-136107

Fmoc-Phe-Lys(Trt)-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Fmoc-Phe-Lys(Trt)-PAB-PNP

Cat. No.: HY-129350

Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

Fmoc-Val-Ala-PAB-OH

Cat. No.: HY-126353

Fmoc-Val-Ala-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.01%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Fmoc-Val-Ala-PAB-PNP

Cat. No.: HY-136136

Fmoc-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-Val-Cit-PAB

Cat. No.: HY-19318

Fmoc-Val-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).



Purity: 97.15%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 1 g

Fmoc-Val-Cit-PAB-PNP

Cat. No.: HY-41189

Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 95.87%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Fmoc-Val-D-Cit-PAB

Cat. No.: HY-19318A

Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Folate-PEG3-amine

Cat. No.: HY-138484

Folate-PEG3-amine is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gly-Gly-Gly-PEG3-TCO

Cat. No.: HY-141190

Gly-Gly-Gly-PEG3-TCO is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Gly-Gly-Gly-PEG4-azide

Cat. No.: HY-145066

Gly-Gly-Gly-PEG4-azide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Gly-Gly-Gly-PEG4-DBCO

Cat. No.: HY-140309

Gly-Gly-Gly-PEG4-DBCO is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 5 mg, 10 mg

Gly-Gly-Gly-PEG4-methyltetrazine

Cat. No.: HY-141284

Gly-Gly-Gly-PEG4-methyltetrazine is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Gly-PEG3-amine

Cat. No.: HY-140244

Gly-PEG3-amine is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

H-cis-Hyp-OMe hydrochloride

Cat. No.: HY-W016429

H-cis-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-cis-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

H-Glu-OtBu

Cat. No.: HY-W018154

H-Glu-OtBu is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Glu-OtBu is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2].



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 g

H-Hyp-OMe hydrochloride

Cat. No.: HY-76043

H-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[c].



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

Hydroxy-PEG1-acid

Cat. No.: HY-116655

Hydroxy-PEG1-acid is a non-cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxy-PEG10-acid

(HO-PEG10-CH2CH2COOH)

Cat. No.: HY-133307

Hydroxy-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Hydroxy-PEG10-Boc

Cat. No.: HY-W019939

Hydroxy-PEG10-Boc is extacted from patent CN108707228 (example 0024). Hydroxy-PEG10-Boc is a uncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel (HY-B0015) or docetaxel (HY-B0011).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxy-PEG2-(CH2)2-Boc

Cat. No.: HY-W067061

Hydroxy-PEG2-(CH2)2-Boc is a uncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Hydroxy-PEG3-(CH2)2-Boc

Cat. No.: HY-42488

Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Hydroxy-PEG3-SS-PEG3-alcohol

Cat. No.: HY-130546

Hydroxy-PEG3-SS-PEG3-alcohol is also a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxy-PEG4-(CH2)2-Boc

Cat. No.: HY-W039178

Hydroxy-PEG4-(CH2)2-Boc is a uncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 191).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Hydroxy-PEG4-acid

Cat. No.: HY-117104

Hydroxy-PEG4-acid is a non-cleavable 4 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-acid is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hynic-PEG3-N3

Cat. No.: HY-130954

Hynic-PEG3-N3 is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 50 mg, 100 mg, 250 mg

HyNic-PEG4-alkyne

Cat. No.: HY-136075

HyNic-PEG4-alkyne is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

LC-PEG8-SPDP

Cat. No.: HY-126497

LC-PEG8-SPDP is a cleavable ADC linker used for the antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-C-tri(CH2-PEG1-NHS ester)

Cat. No.: HY-44149

m-C-tri(CH2-PEG1-NHS ester) is a non-cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

m-PEG10-acid

Cat. No.: HY-140500

m-PEG10-acid is a non-cleavable 10 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-acid is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG10-alcohol

(Decaethylene glycol monomethyl ether)

Cat. No.: HY-141218

m-PEG10-alcohol (Decaethylene glycol monomethyl ether) is a non-cleavable 10 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-alcohol is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG10-amine

Cat. No.: HY-140226

m-PEG10-amine is a non-cleavable 10 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG10-amine is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG11-acid

Cat. No.: HY-140501

m-PEG11-acid is a non-cleavable 11 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG11-acid is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG11-Amine

Cat. No.: HY-W040222

m-PEG11-Amino is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG11-Amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG12-amine

Cat. No.: HY-140227

m-PEG12-amine is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs. m-PEG12-amine is also a non-cleavable 12 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG12-OH

Cat. No.: HY-141220

m-PEG12-OH is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs. m-PEG12-OH is also a non-cleavable 12 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG2-Amine

Cat. No.: HY-W008429

m-PEG2-Amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG2-Amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

m-PEG2-Tos

Cat. No.: HY-42745

m-PEG2-Tos is a uncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG2-Tos is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: 96.97%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

m-PEG3-Amine

Cat. No.: HY-W018174

m-PEG3-Amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG3-Amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: 97.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

m-PEG3-CH2CH2COOH

Cat. No.: HY-W067509

m-PEG3-CH2CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG3-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG4-Amine

Cat. No.: HY-W040214

m-PEG4-Amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG4-Amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG4-Boc

Cat. No.: HY-141395

m-PEG4-Boc is a cleavable 4 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). m-PEG4-Boc is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG4-Br

Cat. No.: HY-130161

m-PEG4-Br is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG4-Ms

Cat. No.: HY-130457

m-PEG4-Ms is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG4-Ms is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG5-CH2COOH

Cat. No.: HY-120537

m-PEG5-CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG5-CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG5-Ms

Cat. No.: HY-116186

m-PEG5-Ms is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG5-Ms is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG5-succinimidyl carbonate

Cat. No.: HY-130150

m-PEG5-succinimidyl carbonate is a non-cleavable 5 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG5-succinimidyl carbonate is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG6-Amine

Cat. No.: HY-130408

m-PEG6-Amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG6-Amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG6-azide

Cat. No.: HY-115374

m-PEG6-azide is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG6-CH2CH2CHO

Cat. No.: HY-W035376

m-PEG6-CH2CH2CHO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG6-CH2CH2CHO is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG6-NHS ester

Cat. No.: HY-133066

m-PEG6-NHS ester is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG6-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG6-SS-PEG6-methyl

Cat. No.: HY-140121

m-PEG6-SS-PEG6-methyl is a cleavable 12 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

m-PEG7-Amine

Cat. No.: HY-120237

m-PEG7-Amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG7-Amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG7-CH2CH2CHO

Cat. No.: HY-130185

m-PEG7-CH2CH2CHO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG7-CH2CH2CHO is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG7-CH2CH2COOH

Cat. No.: HY-130151

m-PEG7-CH2CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG7-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG7-Ms

Cat. No.: HY-130528

m-PEG7-Ms is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG7-Ms is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG8-Amine

Cat. No.: HY-W040236

m-PEG8-Amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

m-PEG8-Ms

Cat. No.: HY-117031

m-PEG8-Ms is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG8-Ms is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG8-NHS ester

Cat. No.: HY-W019793

m-PEG8-NHS ester is a non-cleavable 8 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG9-Amine

Cat. No.: HY-130571

m-PEG9-Amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. m-PEG9-Amine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

MAC glucuronide linker-1

Cat. No.: HY-44221

MAC glucuronide linker-1 is a claevable **ADC linker** for antibody-drug-conjugations (ADCs).



Purity: 95.91%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

MAC glucuronide linker-2

Cat. No.: HY-44222

MAC glucuronide linker-2 is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.38%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

Mal-Ala-Ala-PAB-PNP

Cat. No.: HY-139856

Mal-Ala-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-amido-(CH2COOH)2

Cat. No.: HY-23642

Mal-amido-(CH2COOH)2, compound 7a, is a maleimidoethyl-containing intermediate for hydrophilic **ADC** linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-amido-PEG1-C2-NHS ester

Cat. No.: HY-126507

Mal-amido-PEG1-C2-NHS ester is a nonclaevable **ADC** linker containing a maleimide group and an NHS ester. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 100 mg

Mal-amido-PEG10-C2-NHS ester

Cat. No.: HY-126509

Mal-amido-PEG10-C2-NHS ester is a nonclaevable **ADC** linker containing a maleimide group and an NHS ester. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules.

Purity: 95.23%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

Mal-amido-PEG2-NHS ester

Cat. No.: HY-W040289

Mal-amido-PEG2-NHS ester is a nonclaevable **ADC** linker containing a maleimide group and an NHS ester. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules.

Purity: 98.14%
Clinical Data: No Development Reported
Size: 1 g, 10 g

Mal-amido-PEG2-Val-Cit-PAB-OH

Cat. No.: HY-140146

Mal-amido-PEG2-Val-Cit-PAB-OH is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-amido-PEG2-Val-Cit-PAB-PNP

Cat. No.: HY-140147

Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-amido-PEG3-C1-PFP ester

Cat. No.: HY-133574

Mal-amido-PEG3-C1-PFP ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-amido-PEG3-C1-NHS ester

Cat. No.: HY-133582

Mal-amido-PEG3-C1-NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-amido-PEG5-C2-NHS ester

Cat. No.: HY-126508

Mal-amido-PEG10-C2-NHS ester is a nonclaevable **ADC** linker containing a maleimide group and an NHS ester. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Mal-amido-PEG8-C2-acid

Cat. No.: HY-101159

Mal-amido-PEG8-C2-acid (example 142) is a nonclaevable **ADC** linker, extracted from patent US2018339985.

Purity: 98.72%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

Mal-amido-PEG8-val-gly-PAB-OH

Cat. No.: HY-141146

Mal-amido-PEG8-val-gly-PAB-OH is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-amido-PEG9-Val-Ala-PAB-SG3200

Cat. No.: HY-139956

Mal-amido-PEG9-Val-Ala-PAB-SG3200 is a cleavable ADC linker conjugate used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-bis-PEG3-DBCO

Cat. No.: HY-136087

Mal-bis-PEG3-DBCO is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-C2-Gly3-EDA

Cat. No.: HY-126673

Mal-C2-Gly3-EDA is a cleavable ADC linker containing a Maleimide group. Mal-C2-Gly3-EDA is used for making antibody-drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-C2-NHS ester

Cat. No.: HY-126502

Mal-C2-NHS ester is a noncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg

Mal-CO-PEG5-NHS ester

Cat. No.: HY-133544

Mal-CO-PEG5-NHS ester is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-NH-ethyl-SS-propionic acid

Cat. No.: HY-140120

Mal-NH-ethyl-SS-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.50%
Clinical Data:
Size: 25 mg, 50 mg, 100 mg

Mal-PEG1-acid

Cat. No.: HY-126960

Mal-PEG1-acid is is a non-cleavable 1 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Mal-PEG1-NHS ester

Cat. No.: HY-126886

Mal-PEG1-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG1-NHS ester is PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Mal-PEG1-Val-Cit-OH

Cat. No.: HY-133459

Mal-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-PEG1-Val-Cit-PAB-PNP

Cat. No.: HY-140144

Mal-PEG1-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG1-Val-Cit-PABC-OH

Cat. No.: HY-130944

Mal-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG2-acid

Cat. No.: HY-130442

Mal-PEG2-acid is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-acid can be conjugated to Tubulysin (HY-128914) and its derivative cytotoxic molecule. Mal-PEG2-acid is also a **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG2-bis-PEG3-BCN

Cat. No.: HY-136060

Mal-PEG2-bis-PEG3-BCN is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-PEG2-NHS ester

Cat. No.: HY-126504

Mal-PEG2-NHS ester is a nonclaevable ADC linker containing a Maleimide group, 2-unit PEG and an NHS ester.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 250 mg

Mal-PEG2-Val-Cit-amido-PAB-OH

Cat. No.: HY-130222

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG2-Val-Cit-amido-PAB-OH also can be used as a **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG2-Val-Cit-PABA

Cat. No.: HY-145489

Mal-PEG2-Val-Cit-PABA is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG2-Val-Cit-PABA-PNP

Cat. No.: HY-131156

Mal-PEG2-Val-Cit-PABA-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG2-VCP-NB

Cat. No.: HY-130084

Mal-PEG2-VCP-NB is a claevable **ADC linker** containing a Maleimide group, 2-unit PEG and a VCP NB.



Purity: 95.38%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Mal-PEG3-C1-NHS ester

Cat. No.: HY-133581

Mal-PEG3-C1-NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG3-NHS ester

Cat. No.: HY-129526

Mal-PEG3-NHS ester is a noncleavable ADC linker containing a Maleimide group. Mal-PEG3-NHS ester is used for making antibody-drug conjugate.

Purity: 98.75%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Mal-PEG4-(PEG3-DBCO)-(PEG3-TCO)

Cat. No.: HY-136084

Mal-PEG4-(PEG3-DBCO)-(PEG3-TCO) is a cleavable 10 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG4-bis-PEG3-DBCO

Cat. No.: HY-130971

Mal-PEG4-bis-PEG3-DBCO is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-PEG4-bis-PEG3-methyltetrazine

Cat. No.: HY-130953

Mal-PEG4-bis-PEG3-methyltetrazine is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-PEG4-bis-PEG4-propargyl

Cat. No.: HY-130973

Mal-PEG4-bis-PEG4-propargyl is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-PEG4-PFP ester

Cat. No.: HY-126506

Mal-PEG4-PFP ester is a nonclaevable **ADC linker** containing a Maleimide group, 4-unit PEG and a PFP ester.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG4-VA

Cat. No.: HY-126669

Mal-PEG4-VA is a cleavable **ADC linker** containing a Maleimide group. Mal-PEG4-VA is used for making antibody-drug conjugate.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG4-Val-Cit-PAB

Cat. No.: HY-126672

Mal-PEG4-Val-Cit-PAB is a cleavable **ADC linker** containing a Maleimide group. Mal-PEG4-Val-Cit-PAB is used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG4-Val-Cit-PAB-OH

Cat. No.: HY-140143

Mal-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-PEG4-Val-Cit-PAB-PNP

Cat. No.: HY-140145

Mal-PEG4-Val-Cit-PAB-PNP is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.05%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Mal-PEG4-VC-PAB-DMEA

Cat. No.: HY-126668

Mal-PEG4-VC-PAB-DMEA is a cleavable **ADC linker** containing a Maleimide group. Mal-PEG4-VC-PAB-DMEA is used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mal-PEG6-NHS ester

Cat. No.: HY-130085

Mal-PEG6-NHS ester is a nonclaevable **ADC linker** containing a Maleimide group, 6-unit PEG and a NHS ester.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Mal-Ph-CONH-PEG4-NHS ester

Cat. No.: HY-133545

Mal-Ph-CONH-PEG4-NHS ester is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-Phe-C4-Val-Cit-PAB

Cat. No.: HY-126671

Mal-Phe-C4-Val-Cit-PAB is a cleavable ADC linker containing a Maleimide group.
Mal-Phe-C4-Val-Cit-PAB is used for making antibody-drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-Phe-C4-Val-Cit-PAB-DMEA

Cat. No.: HY-126674

Mal-Phe-C4-Val-Cit-PAB-DMEA is a cleavable ADC linker containing a Maleimide group.
Mal-Phe-C4-Val-Cit-PAB-DMEA is used for making antibody-drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-Sulfo-DBCO

Cat. No.: HY-140306

Mal-Sulfo-DBCO is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mal-PEG4-NHS ester

Cat. No.: HY-126505

Mal-PEG4-NHS ester is a non-cleavable ADC linker which links Quantum dots (QDs) with PEGylated liposomes.

Purity: 99.10%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Maleimide-DOTA

(Maleimido-mono-amide-DOTA)

Cat. No.: HY-133540

Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Maleimide-PEG2-hydrazide TFA

Cat. No.: HY-136097

Maleimide-PEG2-hydrazide (TFA) is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Maleimido-tri(ethylene glycol)-propionic acid

(Mal-PEG3-acid)

Cat. No.: HY-130426

Maleimido-tri(ethylene glycol)-propionic acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.14%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

MC(C5)-Val-Cit

Cat. No.: HY-141143

MC(C5)-Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-AAA-NHCH2OCH2COOH

Cat. No.: HY-132159

MC-AAA-NHCH2OCH2COOH (compound 20) is a cleavable **ADC linker** that is used for making antibody-drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Gly-Gly-Phe

Cat. No.: HY-44235

MC-Gly-Gly-Phe is a cleavable linker used for antibody-drug conjugates (ADC).



Purity: 96.57%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 500 mg

MC-Gly-Gly-Phe-Gly

Cat. No.: HY-44246

MC-Gly-Gly-Phe-Gly is a cleavable **ADC linker** used for antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH

Cat. No.: HY-131990

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mc-Gly-Gly-Phe-Gly-PAB-OH

(Mc-GGFG-PAB-OH)

Cat. No.: HY-136432

Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mc-Gly-Gly-Phe-Gly-PAB-OH TFA

(Mc-GGFG-PAB-OH TFA)

Cat. No.: HY-136432A

Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).



Purity: 96.81%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Mc-Leu-Gly-Arg

Cat. No.: HY-128927

Mc-Leu-Gly-Arg is a cleavable ether linker for antibody-drug conjugates (ADC) design.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Mc-O-Si(di-iso)-Cl

Cat. No.: HY-130817

Mc-O-Si(di-iso)-Cl is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812)).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-PEG2-C2-NHS ester

Cat. No.: HY-126510

MC-PEG2-C2-NHS ester is a nonclaevable 2-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 1 g

MC-Val-Ala-OH

Cat. No.: HY-101153

MC-Val-Ala-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.55%
Clinical Data: No Development Reported
Size: 100 mg

MC-Val-Ala-PAB-PNP

Cat. No.: HY-135975

MC-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

MC-Val-Cit-PAB

Cat. No.: HY-78738

MC-Val-Cit-PAB is a cathepsin cleavable **ADC linker** that is used for making antibody-drug conjugate.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 1 g, 2 g

Mc-Val-Cit-PAB-Cl

Cat. No.: HY-112099

Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE with IC_{50}s of 3.3 and 0.95 nM for BJAB and WSU cell lines in cytotoxicity assay).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg

MC-Val-Cit-PAB-NH-C2-NH-Boc

Cat. No.: HY-132973

MC-Val-Cit-PAB-NH-C2-NH-Boc is a cathepsin cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mc-Val-Cit-PABC-PNP

Cat. No.: HY-20336

Mc-Val-Cit-PABC-PNP is a cathepsin cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mg, 100 mg, 500 mg, 1 g

MC-VC-PAB-Azide

Cat. No.: HY-136138

MC-VC-PAB-Azide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

MC-VC-PAB-NH2

Cat. No.: HY-136132

MC-VC-PAB-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mc-Val-Ala-PAB

Cat. No.: HY-126364

Mc-Val-Ala-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MCC

Cat. No.: HY-132251

MCC is non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as MCC-DM1.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

mDPR(Boc)-Val-Cit-PAB

Cat. No.: HY-126670

mDPR(Boc)-Val-Cit-PAB is a cleavable ADC linker used as a linker for antibody-drug conjugates (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Me-triacetyl-β-D-glucopyranuronate-Ph-ald-NO2

Cat. No.: HY-131086

Me-triacetyl-β-D-glucopyranuronate-Ph-ald-NO2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Me-triacetyl-β-D-glucopyranuronate-Ph-CH2OH-Fmoc

Cat. No.: HY-131087

Me-triacetyl-β-D-glucopyranuronate-Ph-CH2OH-Fmoc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyl 1-Boc-azetidine-3-carboxylate

Cat. No.: HY-40151

Methyl 1-Boc-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Boc-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1].



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Methyl 1-Cbz-azetidine-3-carboxylate

Cat. No.: HY-W019226

Methyl 1-Cbz-azetidine-3-carboxylate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl 1-Cbz-azetidine-3-carboxylate is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1].



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyl azetidine-3-carboxylate hydrochloride

Cat. No.: HY-33615

Methyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs<.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D

Cat. No.: HY-145488

MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methylcyclopropene-PEG3-amine

Cat. No.: HY-136047

Methylcyclopropene-PEG3-amine is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methylcyclopropene-PEG4-NHS

Cat. No.: HY-136048

Methylcyclopropene-PEG4-NHS is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyltetrazine-DBCO

Cat. No.: HY-140313

Methyltetrazine-DBCO is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyltetrazine-Maleimide

Cat. No.: HY-136104

Methyltetrazine-Maleimide is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Methyltetrazine-PEG4-aldehyde

Cat. No.: HY-136074

Methyltetrazine-PEG4-aldehyde is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Methyltetrazine-PEG4-hydrazone-DBCO

Cat. No.: HY-136079

Methyltetrazine-PEG4-hydrazone-DBCO is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Methyltetrazine-PEG4-oxyamine

Cat. No.: HY-136056

Methyltetrazine-PEG4-oxyamine is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyltetrazine-PEG4-SS-NHS ester

Cat. No.: HY-133466

Methyltetrazine-PEG4-SS-NHS ester is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Methyltetrazine-PEG4-SS-PEG4-methyltetrazine

Cat. No.: HY-130943

Methyltetrazine-PEG4-SS-PEG4-methyltetrazine is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Methyltetrazine-SS-NHS

Cat. No.: HY-136033

Methyltetrazine-SS-NHS is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Methyltetrazine-SS-PEG4-Biotin

Cat. No.: HY-136035

Methyltetrazine-SS-PEG4-Biotin is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MP-PEG4-VK(Boc)G-OSu

Cat. No.: HY-132163

MP-PEG4-VK(Boc)G-OSu is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mp-polymer ester

Cat. No.: HY-128970

Mp-polymer ester is a noncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N,N-Bis(PEG2-alkyne)-N-amido-PEG2-thiol

Cat. No.: HY-136130

N,N-Bis(PEG2-alkyne)-N-amido-PEG2-thiol is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N,N-Bis(PEG2-N3)-N-amido-PEG2-thiol

Cat. No.: HY-136129

N,N-Bis(PEG2-N3)-N-amido-PEG2-thiol is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N-(5-Hydroxypentyl)maleimide

Cat. No.: HY-130818

N-(5-Hydroxypentyl)maleimide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812)).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

N-(Iodoacetamido)-Doxorubicin

Cat. No.: HY-141158

N-(Iodoacetamido)-Doxorubicin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-cis-4-Hydroxy-D-proline

Cat. No.: HY-W002887

N-Boc-cis-4-Hydroxy-D-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-Hydroxy-D-proline is also a alkyl chain-based PROTAC linker that can be used in the synth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

N-Boc-cis-4-hydroxy-D-proline methyl ester

Cat. No.: HY-W002680

N-Boc-cis-4-hydroxy-D-proline methyl ester is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-hydroxy-D-proline methyl ester is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1].



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

N-Boc-cis-4-hydroxy-L-proline

Cat. No.: HY-W002886

N-Boc-cis-4-hydroxy-L-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-hydroxy-L-proline is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2].



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 500 mg

N-Boc-cis-4-hydroxy-L-proline methyl ester

Cat. No.: HY-Y0755

N-Boc-cis-4-hydroxy-L-proline methyl ester is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-hydroxy-L-proline methyl ester is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2].



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

N-Boc-diethanolamine

Cat. No.: HY-W044078

N-Boc-diethanolamine is an Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-diethanolamine is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

N-Boc-N-bis(PEG2-OH)

Cat. No.: HY-117079

N-Boc-N-bis(PEG2-OH) is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-N-bis(PEG2-OH) is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-N-bis(PEG4-OH)

Cat. No.: HY-130449

N-Boc-N-bis(PEG4-OH) is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-N-bis(PEG4-OH) is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-PEG2-bromide

Cat. No.: HY-130503

N-Boc-PEG2-bromide is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-PEG2-bromide is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg

N-Boc-PEG3-bromide

Cat. No.: HY-W006445

N-Boc-PEG3-bromide is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-PEG3-bromide is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-PEG4-bromide

Cat. No.: HY-W046471

N-Boc-PEG4-bromide is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-PEG4-bromide is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 250 mg

N-Boc-PEG5-bromide

Cat. No.: HY-120702

N-Boc-PEG5-bromide is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-PEG5-bromide is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-PEG6-alcohol

Cat. No.: HY-W071584

N-Boc-PEG6-alcohol is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-PEG6-alcohol is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

N-Boc-PEG7-alcohol

Cat. No.: HY-130505

N-Boc-PEG7-alcohol is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-PEG7-alcohol is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-PEG9-alcohol

Cat. No.: HY-W071583

N-Boc-PEG9-alcohol is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. N-Boc-PEG9-alcohol is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Boc-Val-Dil-Dap-Doe

Cat. No.: HY-130976

N-Boc-Val-Dil-Dap-Doe is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Bromoacetyl-β-alanine

Cat. No.: HY-141379

N-Bromoacetyl-β-alanine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. N-Bromoacetyl-β-alanine is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

N-Butanoyl-L-homoserine lactone

(C4-HSL; N-Butyryl-L-homoserine lactone)

Cat. No.: HY-114816

N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).
N-Butanoyl-L-homoserine lactone has **antibacterial** activity and is used in antibacterial biofilm.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

N-butyryl-L-Homoserine lactone-d5

Cat. No.: HY-114816S

N-butyryl-L-Homoserine lactone-d5 is the deuterium labeled N-Butanoyl-L-homoserine lactone.
N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Hydroxysulfosuccinimide sodium

Cat. No.: HY-W002213

N-Hydroxysulfosuccinimide (sodium) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

N-Succinimidyl 3-(Bromoacetamido)propionate

(3-(2-Bromoacetamido)propanoic acid NHS ester) Cat. No.: HY-141385

N-Succinimidyl 3-(Bromoacetamido)propionate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. N-Succinimidyl 3-(Bromoacetamido)propionate is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Succinimidyloxycarbonylpropyl methanethiosulfonate

(NHS-C4-MTS) Cat. No.: HY-130112

N-Succinimidyloxycarbonylpropyl methanethiosulfonate is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline

Cat. No.: HY-77593

N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-tert-Butoxycarbonyl-trans-4-hydroxy-D-proline is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 5 g

N-trifluoroacetyl-β-alanyl chloride

Cat. No.: HY-138322

N-trifluoroacetyl-β-alanyl chloride is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-C2-NHS ester

Cat. No.: HY-126520

N3-C2-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

N3-C3-NHS ester

Cat. No.: HY-126521

N3-C3-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.46%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

N3-C4-NHS ester

Cat. No.: HY-126522

N3-C4-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

N3-C5-NHS ester

Cat. No.: HY-126523

N3-C5-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.04%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

N3-PEG2-C2-NHS ester

Cat. No.: HY-126526

N3-PEG2-C2-NHS ester is a nonclaevable 2-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

N3-PEG2-C2-PFP ester

Cat. No.: HY-126527

N3-PEG2-C2-PFP ester is a nonclaevable 2-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG3-C2-NHS ester

Cat. No.: HY-126528

N3-PEG3-C2-NHS ester is a nonclaevable 3-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

N3-PEG3-C2-PFP ester

Cat. No.: HY-126529

N3-PEG3-C2-PFP ester is a nonclaevable 3-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG3-CH2CH2-Boc

Cat. No.: HY-42489

N3-PEG3-CH2CH2-Boc is a cleavable 3 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). N3-PEG3-CH2CH2-Boc is also a PEG- and Alkyl/ether-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG3-CH2CH2COOH

Cat. No.: HY-42490

N3-PEG3-CH2CH2COOH a PEG-based **PROTAC** linker can be used in the synthesis of BI-3663 (HY-111546), BI-4216 and BI-0319. Azido-PEG3-acid is also a non-cleavable 3 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

N3-PEG4-amido-Lys(Fmoc)-acid

Cat. No.: HY-136058

N3-PEG4-amido-Lys(Fmoc)-acid is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N3-PEG4-C2-NHS ester

Cat. No.: HY-130109

N3-PEG4-C2-NHS ester is a nonclaevable 4-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg

N3-PEG4-C2-Pfp ester

Cat. No.: HY-130108

N3-PEG4-C2-Pfp ester is a nonclaevable 4-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

N3-PEG5-aldehyde

Cat. No.: HY-136054

N3-PEG5-aldehyde is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

N3-Ph-NHS ester

Cat. No.: HY-126524

N3-Ph-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.55%
Clinical Data: No Development Reported
Size: 100 mg

NH-bis(C1-Boc)

Cat. No.: HY-23641

NH-bis(C1-Boc)is a uncleavable linker used for antibody-drug conjugates (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NH-bis-PEG2

Cat. No.: HY-130328

NH-bis-PEG2 is a non-cleavable 2 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). NH-bis-PEG2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NH2-C5-PEG4-N3-L-Lysine-PEG3-N3

Cat. No.: HY-130946

NH2-C5-PEG4-N3-L-Lysine-PEG3-N3 is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NH2-PEG2-C2-Boc

Cat. No.: HY-42149

NH2-PEG2-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG2-C2-Boc is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg

NH2-PEG4-CH2CH2COOH

Cat. No.: HY-W021787

NH2-PEG4-CH2CH2COOH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG4-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

NH2-PEG4-hydrazone-DBCO

Cat. No.: HY-136131

NH2-PEG4-hydrazone-DBCO is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 25 mg, 50 mg

NH2-PEG4-Lys(Boc)-NH-(m-PEG24)

Cat. No.: HY-140242

NH2-PEG4-Lys(Boc)-NH-(m-PEG24) is a cleavable 28 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

NH2-PEG5-OH

Cat. No.: HY-129637

NH2-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG5-OH is also a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

NH2-PEG6-Boc

Cat. No.: HY-130486

NH2-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. NH2-PEG6-Boc is also a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

NH2-PEG6-CH2CH2COOH

Cat. No.: HY-W040257

NH2-PEG6-CH2CH2COOH is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG6-CH2CH2COOH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg

NH2-PEG9-acid

Cat. No.: HY-W019798

NH2-PEG9-acid is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH2-PEG9-acid also is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

NHPI-PEG2-C2-NHS ester

Cat. No.: HY-130095

NHPI-PEG2-C2-NHS ester is a nonclaevable 2-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

NHPI-PEG2-C2-Pfp ester

Cat. No.: HY-130094

NHPI-PEG2-C2-Pfp ester is a nonclaevable 2-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

NHPI-PEG3-C2-NHS ester

Cat. No.: HY-130093

NHPI-PEG3-C2-NHS ester is a nonclaevable 3-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

NHPI-PEG3-C2-Pfp ester

Cat. No.: HY-130092

NHPI-PEG3-C2-Pfp ester is a nonclaevable 3-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

NHPI-PEG4-C2-NHS ester

Cat. No.: HY-130091

NHPI-PEG4-C2-NHS ester, example 40 (WO2014185985A1), is used as a linker for antibody-drug conjugates (**ADC**).

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

NHPI-PEG4-C2-Pfp ester

Cat. No.: HY-130090

NHPI-PEG4-C2-Pfp ester is used as a linker for antibody-drug conjugates (**ADC**).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

NHS-PEG2-SS-PEG2-NHS

Cat. No.: HY-136133

NHS-PEG2-SS-PEG2-NHS is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

NHS-SS-biotin

Cat. No.: HY-140129

NHS-SS-biotin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥98.0%
Clinical Data:
Size: 25 mg

NO2-SPDB-sulfo

Cat. No.: HY-133548

NO2-SPDB-sulfo is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NO2-SPDMV

Cat. No.: HY-W071007

NO2-SPDMV is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

NO2-SPDMV-sulfo

Cat. No.: HY-133549

NO2-SPDMV-sulfo is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NO2-SPP

Cat. No.: HY-129367

NO2-SPP is a cleavable linker that is used for making antibody-drug conjugate **(ADC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NO2-SPP-sulfo

Cat. No.: HY-133547

NO2-SPP-sulfo is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NO2-SPP-sulfo-Me

Cat. No.: HY-129378

NO2-SPP-sulfo-Me is a cleavable linker that is used for making antibody-drug conjugate **(ADC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Oleoyl-Gly-Lys-N-(m-PEG11)

Cat. No.: HY-141292

Oleoyl-Gly-Lys-N-(m-PEG11) is a cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

OPSS-PEG36-acid

Cat. No.: HY-141355

OPSS-PEG36-acid is a cleavable 36 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

OPSS-Val-Cit-PAB-OH

Cat. No.: HY-141144

OPSS-Val-Cit-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OPSS-Val-Cit-PAB-PNP

Cat. No.: HY-141145

OPSS-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

PC Alkyne-PEG4-NHS ester

Cat. No.: HY-140139

PC Alkyne-PEG4-NHS ester is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

PC Biotin-PEG3-alkyne

Cat. No.: HY-140130

PC Biotin-PEG3-alkyne is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

PC Biotin-PEG3-azide

Cat. No.: HY-140132

PC Biotin-PEG3-azide is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 5 mg, 10 mg, 50 mg, 100 mg

PC Biotin-PEG3-NHS ester

Cat. No.: HY-140134

PC Biotin-PEG3-NHS ester is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PC DBCO-PEG3-biotin

Cat. No.: HY-140136

PC DBCO-PEG3-biotin is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

PC Mal-NHS carbonate ester

Cat. No.: HY-140140

PC Mal-NHS carbonate ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PC SPDP-NHS carbonate ester

Cat. No.: HY-140138

PC SPDP-NHS carbonate ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

PC-Biotin-PEG4-PEG3-azide

Cat. No.: HY-140133

PC-Biotin-PEG4-PEG3-azide is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDB-Pfp

Cat. No.: HY-129366

PDB-Pfp is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 1 g

PDdB-Pfp

Cat. No.: HY-129372

PDdB-Pfp is a cleavable **ADC linker** used for the agents that target for the extracellular loop 1 (ECL1) of TM4SF1 (transmembrane 4 L6 family member 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

PDdEC-NB

Cat. No.: HY-126519

PDdEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

PDEC-NB

Cat. No.: HY-126498

PDEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (**ADC**).



Purity: 98.04%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

PDP-C1-Ph-Val-Cit

Cat. No.: HY-126533

PDP-C1-Ph-Val-Cit is a cleavable **ADC linker** used for antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

PDP-Pfp

Cat. No.: HY-129359

PDP-Pfp is a reducible ADC linker used for the agents that target for the extracellular loop 1 (ECL1) of **TM4SF1** (transmembrane 4 L6 family member 1).



Purity: 98.66%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

PEG12-Tos

Cat. No.: HY-117050

Tos-PEG12 is a noncleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). PEG12-Tos is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PEG4-SPDP

Cat. No.: HY-126496

PEG4-SPDP is a cleavable **ADC linker** used for the antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Phe-Lys(Fmoc)-PAB

Cat. No.: HY-129362

Phe-Lys(Fmoc)-PAB is a cathepsin cleavable **ADC linker** used for the antibody-drug conjugates (ADCs).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 mg

Phe-Lys(Trt)-PAB

Cat. No.: HY-129349

Phe-Lys(Trt)-PAB is a cathepsin cleavable **ADC linker** used for the antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

PPA

Cat. No.: HY-141664

PPA is an **ADC linker** (US20060073528A1). PPA can be used for making antibody-drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PPC-NB

Cat. No.: HY-126530

PPC-NB is a glutathione cleavable **linker** used for the antibody-drug conjugate **(ADC)**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 100 mg

PPC-NHS ester (2,5-Dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate)

Cat. No.: HY-W071006

PPC-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.32%
Clinical Data: No Development Reported
Size: 100 mg, 1 g

Propargyl-C1-NHS ester

Cat. No.: HY-126511

Propargyl-C1-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC).



Purity: 95.12%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

Propargyl-C2-NHS ester

Cat. No.: HY-126512

Propargyl-C2-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC).



Purity: 96.60%
Clinical Data: No Development Reported
Size: 100 mg

Propargyl-C8-amido-PEG2-NHS ester

Cat. No.: HY-133539

Propargyl-C8-amido-PEG2-NHS ester is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-NH-PEG3-C2-NHS ester

Cat. No.: HY-130931

Propargyl-NH-PEG3-C2-NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-O-C1-amido-PEG2-C2-NHS ester

Cat. No.: HY-126514

Propargyl-O-C1-amido-PEG2-C2-NHS ester is a nonclaevable 2-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Propargyl-O-C1-amido-PEG3-C2-NHS ester

Cat. No.: HY-133583

Propargyl-O-C1-amido-PEG3-C2-NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-O-C1-amido-PEG4-C2-NHS ester

Cat. No.: HY-126515

Propargyl-O-C1-amido-PEG4-C2-NHS ester is a nonclaevable 4-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Propargyl-PEG1-NHS ester

Cat. No.: HY-126513

Propargyl-PEG1-NHS ester is a nonclaevable 1-unit PEG linker for antibody-drug-conjugation (ADC).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Propargyl-PEG1-SS-alcohol

Cat. No.: HY-140108

Propargyl-PEG1-SS-alcohol is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Propargyl-PEG1-SS-PEG1-acid

Cat. No.: HY-140109

Propargyl-PEG1-SS-PEG1-acid is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Propargyl-PEG1-SS-PEG1-C2-Boc

Cat. No.: HY-130690

Propargyl-PEG1-SS-PEG1-C2-Boc is a Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs.
Propargyl-PEG1-SS-PEG1-C2-Boc is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG1-SS-PEG1-PFP ester

Cat. No.: HY-140110

Propargyl-PEG1-SS-PEG1-PFP ester is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG1-SS-PEG1-propargyl

Cat. No.: HY-140111

Propargyl-PEG1-SS-PEG1-propargyl is a cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Propargyl-PEG2-acid

Cat. No.: HY-118764

Propargyl-PEG2-acid is a non-cleavable 2 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-acid is also a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Propargyl-PEG2-amine

Cat. No.: HY-W051634

Propargyl-PEG2-amine is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Propargyl-PEG2-NHBoc

Cat. No.: HY-118808

Propargyl-PEG2-NHBoc is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-NHBoc is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG3-acid

Cat. No.: HY-126975

Propargyl-PEG3-acid is a non-cleavable (3 unit PEG) ADC linker and also a PEG-based PROTAC linker that can be used to synthesis 6-OHDA-PEG3-yne. 6-OHDA-PEG3-yne contains 6-OHDA (HY-B1081, HY-B1081A) and Propargyl-PEG3-acid.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Propargyl-PEG3-NHS ester

Cat. No.: HY-126974

Propargyl-PEG3-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG3-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG4-Br

Cat. No.: HY-130591

Propargyl-PEG4-Br is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.
Propargyl-PEG4-Br is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 mg

Propargyl-PEG4-CH2CH2-Boc

Cat. No.: HY-130293

Propargyl-PEG4-CH2CH2-Boc is a non-cleavable **ADC linker** that can be used to synthesize ADC inhibitors of Galectin-3.
Propargyl-PEG4-CH2CH2-Boc is a **PEG**- and **Alkyl/ether**-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG4-hydrazide

Cat. No.: HY-133427

Propargyl-PEG4-hydrazide is a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG4-NHS ester

Cat. No.: HY-126516

Propargyl-PEG4-NHS ester is a nonclaevable 4-unit PEG linker for antibody-drug-conjugation (ADC).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG4-thiol

Cat. No.: HY-116427

Propargyl-PEG4-thiol is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG4-thiol is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG4-Tos

Cat. No.: HY-130387

Propargyl-PEG4-Tos is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG4-Tos is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG5-acid

Cat. No.: HY-101157

Propargyl-PEG5-acid is a non-cleavable 5 unit PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-acid can used to synthesize ADC inhibitors of Galectin-3. Propargyl-PEG5-acid is a PEG-based **PROTAC linker** that can be used in the synthesis of PROTACs.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Propargyl-PEG5-amine

Cat. No.: HY-126976

Propargyl-PEG5-amine is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-amine is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Propargyl-PEG5-NHS ester

Cat. No.: HY-130388

Propargyl-PEG5-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG5-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Propargyl-PEG6-acid

Cat. No.: HY-130386

Propargyl-PEG6-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG6-acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG6-NHS ester

Cat. No.: HY-130385

Propargyl-PEG6-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG6-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG7-acid

Cat. No.: HY-130383

Propargyl-PEG7-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG7-acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG7-NHS ester

Cat. No.: HY-130381

Propargyl-PEG7-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG7-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG8-acid

Cat. No.: HY-130379

Propargyl-PEG8-acid is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG8-acid is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). The ADCs can be used in bacterial infections caused by Gram-negative bacteria.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG8-bromide

Cat. No.: HY-130377

Propargyl-PEG8-bromide is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG8-bromide is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG8-NH2

Cat. No.: HY-130182

Propargyl-PEG8-NH2 (compound 3b) is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG8-NH2 is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG8-NHS ester

Cat. No.: HY-130376

Propargyl-PEG8-NHS ester is a PEG/Alkyl/ether-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG8-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-PEG9-bromide

Cat. No.: HY-130372

Propargyl-PEG9-bromide is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. Propargyl-PEG9-bromide is a non-cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propargyl-Tos

Cat. No.: HY-79584

Propargyl-Tos is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PTAD-PEG4-alkyne

Cat. No.: HY-136046

PTAD-PEG4-alkyne is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

PTAD-PEG4-amine

Cat. No.: HY-135961

PTAD-PEG4-amine is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

PTAD-PEG4-N3

Cat. No.: HY-130940

PTAD-PEG4-N3 is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Py-ds-dmBut-amido-PEG4-NHS ester

Cat. No.: HY-136157

Py-ds-dmBut-amido-PEG4-NHS ester is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Py-ds-Prp-Osu

Cat. No.: HY-136102

Py-ds-Prp-Osu is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

Cat. No.: HY-129942

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione cleavable **ADC linker** used for the antibody-drug conjugates (ADCs) and refers to the Alkyl-Chain composition.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

SC-Val-Cit-PAB

Cat. No.: HY-126667

SC-Val-Cit-PAB is a cleavable **ADC linker** for antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIA Crosslinker

Cat. No.: HY-W011541

SIA Crosslinker is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMCC

Cat. No.: HY-42360

SMCC is a protein crosslinker. SMCC-conjugated antigen coupled spleen cells to induce antigen-specific immune responses.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 100 mg

SMPT

Cat. No.: HY-126405

SMPT is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.07%
Clinical Data: No Development Reported
Size: 100 mg

SNPB

Cat. No.: HY-129365

SNPB is a cleavable linker that is used for making antibody-drug conjugate **(ADC)**.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

SNPB-sulfo-Me

Cat. No.: HY-129375

SNPB-sulfo-Me is a cleavable linker that is used for making antibody-drug conjugate **(ADC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

SPDB

Cat. No.: HY-12448

SPDB is a glutathione cleavable **ADC linker** used for the antibody-drug conjugate (ADCs).



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SPDB-sulfo

Cat. No.: HY-129370

SPDB-sulfo is a glutathione cleavable **ADC linker** used for the antibody-drug conjugate (ADCs) .



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

SPDH

Cat. No.: HY-129374

SPDH is a cleavable ADC linker used for diagnosis and treatment of cancer or B cell proliferative diseas.

Purity: 98.57%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

SPDMB

Cat. No.: HY-129369

SPDMB is a glutathione cleavable **ADC linker** used for the antibody-drug conjugate (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

SPDMV

Cat. No.: HY-129368

SPDMV is a glutathione cleavable **ADC linker** used for the antibody-drug conjugate (ADCs).



Purity: 95.49%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

SPDMV-sulfo

Cat. No.: HY-129373

SPDMV-sulfo is a glutathione cleavable **ADC linker** used for the antibody-drug conjugate (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

SPDP

(SPDP Crosslinker)

Cat. No.: HY-100216

SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

SPDP-C6-Gly-Leu-NHS ester

Cat. No.: HY-141123

SPDP-C6-Gly-Leu-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

SPDP-PEG12-acid

Cat. No.: HY-141353

SPDP-PEG12-acid is a cleavable 12 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

SPDP-PEG36-NHS ester

Cat. No.: HY-141358

SPDP-PEG36-NHS ester is a cleavable 36 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SPDP-sulfo

Cat. No.: HY-133543

SPDP-sulfo is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SPDV

Cat. No.: HY-129371

SPDV is a cleavable ADC linker used for diagnosis and treatment of cancer or B cell proliferative diseas.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g

SPP

Cat. No.: HY-128926

SPP is a cleavable disulfide linker, can be used to form cytotoxic compound- linker conjugate.



Purity: 97.65%
Clinical Data:
Size: 100 mg, 1 g

SS-bis-amino-PEG4-NHS ester

Cat. No.: HY-136134

SS-bis-amino-PEG4-NHS ester is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Succinic anhydride

Cat. No.: HY-79369

Succinic anhydride is a cyclic anhydride and a nonclaevable **ADC linker** extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the prodrug to an amine or hydroxy 1 group of a targeting polypeptide.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Succinic anhydride-d4

Cat. No.: HY-79369S

Succinic anhydride-d4 is the deuterium labeled Succinic anhydride. Succinic anhydride is a cyclic anhydride and a nonclaevable **ADC linker** extracted from patent WO2009064913A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfo-DMAC-SPP

Cat. No.: HY-130110

Sulfo-DMAC-SPP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Sulfo-LC-SPDP

Cat. No.: HY-126495

Sulfo-LC-SPDP is a heterobifunctional, thiol-cleavable and membrane impermeable crosslinker.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Sulfo-SIAB

Cat. No.: HY-129525

Sulfo-SIAB is a nonclaevable monovalent bilinker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 10 g

Sulfo-SIAB sodium

Cat. No.: HY-129525A

Sulfo-SIAB sodium is a nonclaevable monovalent bilinker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 10 g

Sulfo-SMCC sodium

Cat. No.: HY-D0975

Sulfo-SMCC sodium is a commonly used hetero-bifunctional, noncleavable ADC crosslinker bearing N-hydroxysuccinimide (NHS) ester and maleimide groups to react with primary amines and sulfhydryl groups, respectively.



Purity: 97.71%
Clinical Data: No Development Reported
Size: 10 mg

Sulfo-SMPB sodium

Cat. No.: HY-129655

Sulfo-SMPB sodium is a non-cleavable, heterobifunctional chemical cross-linking reagent which contains N-hydroxysuccinimide (NHS) ester and maleimide groups, allowing covalent conjugation of amine- and sulfhydryl-containing molecules.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfo-SNPB

Cat. No.: HY-129376

Sulfo-SNPB is a cleavable linker that is used for making antibody-drug conjugate **(ADC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

sulfo-SPDB

Cat. No.: HY-101151

sulfo-SPDB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Sulfo-SPDP-C6-NHS sodium

Cat. No.: HY-126495A

Sulfo-SPDP-C6-NHS sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfo-SPP

Cat. No.: HY-129377

Sulfo-SPP is a heterobifunctional, thiol-cleavable and membrane impermeable crosslinker.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

tans-4-Hydroxy-D-proline hydrochloride

Cat. No.: HY-W003511

tans-4-Hydroxy-D-proline hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). tans-4-Hydroxy-D-proline hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PR.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

tans-4-Hydroxy-D-proline methyl ester hydrochloride

Cat. No.: HY-W006629

tans-4-Hydroxy-D-proline methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

TCO-PEG1-Val-Cit-OH

Cat. No.: HY-130934

TCO-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-PEG1-Val-Cit-PABC-OH

Cat. No.: HY-130966

TCO-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

TCO-PEG1-Val-Cit-PABC-PNP

Cat. No.: HY-136100

TCO-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

TCO-PEG12-NHS ester

Cat. No.: HY-141170

TCO-PEG12-NHS ester is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. TCO-PEG12-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-PEG3-aldehyde

Cat. No.: HY-136077

TCO-PEG3-aldehyde is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-PEG3-Biotin

Cat. No.: HY-136050

TCO-PEG3-Biotin is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

TCO-PEG3-CH2-aldehyde

Cat. No.: HY-136076

TCO-PEG3-CH2-aldehyde is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

TCO-PEG4-DBCO

Cat. No.: HY-140310

TCO-PEG4-DBCO is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. TCO-PEG4-DBCO is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-PEG4-NHS ester

Cat. No.: HY-141167

TCO-PEG4-NHS ester is a PEG-based **PROTAC linker** can be used in the synthesis of PROTACs. TCO-PEG4-NHS ester is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).

Purity: 99.58%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCO-SS-amine

Cat. No.: HY-136039

TCO-SS-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetraethylene glycol monotosylate

(Tos-PEG4)

Cat. No.: HY-41541

Tetraethylene glycol monotosylate is a cleavable and acylhydrazone-based **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Tetraethylene glycol monotosylate also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrazine-biotin

Cat. No.: HY-136095

Tetrazine-biotin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tetrazine-diazo-PEG4-biotin

Cat. No.: HY-136078

Tetrazine-diazo-PEG4-biotin is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-PEG4-amine hydrochloride

Cat. No.: HY-130977

Tetrazine-PEG4-amine (hydrochloride) is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 95.15%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Tetrazine-PEG4-biotin

Cat. No.: HY-136053

Tetrazine-PEG4-biotin is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-PEG4-oxyamine hydrochloride

Cat. No.: HY-136052

Tetrazine-PEG4-oxyamine (hydrochloride) is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-PEG4-SS-NHS

Cat. No.: HY-136040

Tetrazine-PEG4-SS-NHS is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 90.21%
Clinical Data:
Size: 10 mg

Tetrazine-PEG4-SS-Py

Cat. No.: HY-130947

Tetrazine-PEG4-SS-Py is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-PEG5-SS-amine

Cat. No.: HY-130945

Tetrazine-PEG5-SS-amine is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-PEG6-amine hydrochloride

Cat. No.: HY-136086

Tetrazine-PEG6-amine (hydrochloride) is a cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-Ph-OPSS

Cat. No.: HY-130928

Tetrazine-Ph-OPSS is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrazine-Ph-SS-amine

Cat. No.: HY-133504

Tetrazine-Ph-SS-amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-SS-Biotin

Cat. No.: HY-136031

Tetrazine-SS-Biotin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrazine-SS-NHS

Cat. No.: HY-136032

Tetrazine-SS-NHS is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tetrazine-SS-PEG4-Biotin

Cat. No.: HY-136036

Tetrazine-SS-PEG4-Biotin is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

THP-PEG6-OH

Cat. No.: HY-126918

THP-PEG6-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. THP-PEG6-OH is also a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

THP-SS-alcohol

Cat. No.: HY-140122

THP-SS-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

THP-SS-PEG1-Boc

Cat. No.: HY-140123

THP-SS-PEG1-Boc is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

THP-SS-PEG1-Tos

Cat. No.: HY-140124

THP-SS-PEG1-Tos is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Tr-PEG2-OH

Cat. No.: HY-114995

Tr-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Tr-PEG2-OH is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG3-OH

Cat. No.: HY-120258

Tr-PEG3-OH is a non-cleavable 3 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG5-OH

Cat. No.: HY-120845

Tr-PEG5-OH is a non-cleavable 5 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG6-OH

Cat. No.: HY-129311

Tr-PEG6-OH is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG8-OH

Cat. No.: HY-130165

Tr-PEG8-OH is a non-cleavable 8 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG8-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

trans-Sulfo-SMCC

Cat. No.: HY-126503

trans-Sulfo-SMCC is a non-cleavable and membrane permeable ADC crosslinker.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

Cat. No.: HY-21577

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine is a cleavable PEG **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane is also a PEG/Alkyl/ether-based **PROTAC linker** that can be used in the synthesis of PROTACs.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 50 mg

Val-Cit

Cat. No.: HY-140014

Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Val-cit-PAB-OH

Cat. No.: HY-12362

Val-cit-PAB-OH is a cleavable ADC linker.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 500 mg, 1 g, 5 g

Vipivotide tetraxetan Linker

(PSMA-617 Linker)

Cat. No.: HY-43869

Vipivotide tetraxetan Linker (PSMA-617 Linker) is a nonclaevable peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Zuvotolimod

Cat. No.: HY-145620

Zuvotolimod is a myeloid cell agonist compound-linker for antibody conjugate. Zuvotolimod can be used in the research of cancer and hepatitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-D-glucuronide-pNP-carbonate

Cat. No.: HY-136329

β-D-glucuronide-pNP-carbonate is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-D-tetraacetylgalactopyranoside-PEG1-N3

Cat. No.: HY-136318

β-D-tetraacetylgalactopyranoside-PEG1-N3 is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Estradiol-6-CMO-PEG3-biotin

Cat. No.: HY-130929

β-Estradiol-6-CMO-PEG3-biotin is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.

All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.

The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.

Antibody-Drug Conjugates (ADCs)

Disitamab vedotin
(RC48) Cat. No.: HY-P9985

Disitamab vedotin (RC48) is an antibody-drug conjugate **(ADC)** comprising a monoclonal antibody against human epidermal growth factor receptor 2 **(HER2)** conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.

Disitamab vedotin

Purity: 97.40%
Clinical Data: Launched
Size: 1 mg, 5 mg

Mal-amido-PEG8-Val-Ala-PAB-SG3200
Cat. No.: HY-139957

Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a site-specific **antibody-drug conjugate** that binds **HER2** (extracted from patent WO2016166300A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-VC-PABC-amide-PEG1-CH2-CC-885
Cat. No.: HY-145448

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugates (ADC) based on protein degrading agent (protac molecular glue, etc.).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sacituzumab govitecan
(IMMU-132) Cat. No.: HY-132254

Sacituzumab govitecan (IMMU-132) is an **antibody-drug conjugate (ADC)** targeting **Trop-2** for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.

Sacituzumab govitecan

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

SC209
Cat. No.: HY-144880

SC209, an **ADC cytotoxin** extracted from patent WO2021247798, is used in synthesis of anti-**EGFR** antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trastuzumab deruxtecan
(DS-8201; DS-8201a) Cat. No.: HY-138298A

Trastuzumab deruxtecan (DS-8201a) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trastuzumab deruxtecan (solution)
(DS-8201 (solution); DS-8201a (solution)) Cat. No.: HY-138298

Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: 98.75%
Clinical Data: Launched
Size: 5 mg (10 mg × mL * 500 μL in Aqμeoμs solμtion)

Trastuzumab emtansine
(Ado-Trastuzumab emtansine; PRO132365; T-DM 1) Cat. No.: HY-P9921

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).

Trastuzumab emtansine

Purity: ≥99.40%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Ugodotin
Cat. No.: HY-139591

Ugodotin is an antibody-drug conjugate. Ugodotin can binds **IGF-1R** with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

(Rac)-Lys-SMCC-DM1

((Rac)-Lys-Nε-MCC-DM1)

Cat. No.: HY-101982A

(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

2',3'-cGAMP-C2-PPA

Cat. No.: HY-141662

2',3'-cGAMP-C2-PPA (45), A cyclic di-nucleotide, is a **STING** agonist (US20210015941A1). 2',3'-cGAMP-C2-PPA is a **drug-linker conjugate for ADC** that can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetylene-linker-Val-Cit-PABC-MMAE

(LCB14-0602)

Cat. No.: HY-19812

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC.

Purity: 95.08
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AcLys-PABC-VC-Aur0101

Cat. No.: HY-111554

AcLys-PABC-VC-Aur0101 is a **drug-linker conjugate for ADC** (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AcLysValCit-PABC-DMAE-SW-163D

Cat. No.: HY-114325

AcLysValCit-PABC-DMAE-SW-163D is a **drug-linker conjugates for ADC** which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminobenzenesulfonic auristatin E

Cat. No.: HY-145989

Aminobenzenesulfonic auristatin E is a **drug-linker conjugate for ADC** with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminooxy CatB-LXR

Cat. No.: HY-144554

Aminooxy CatB-LXR (compound 10) is a drug-linker conjugates for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AmPEG6C2-Aur0131

Cat. No.: HY-111555

AmPEG6C2-Aur0131 is a **drug-linker conjugate for ADC** (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ1508

(MC-Lys-MMETA)

Cat. No.: HY-128962

AZ1508 is a **drug-linker conjugates for ADC** for the treatment of breast and stomach cancer, and the drug is a tubulin inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azide-PEG4-VC-PAB-Doxorubicin

Cat. No.: HY-136288

Azide-PEG4-VC-PAB-Doxorubicin is a drug-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG4-Val-Cit-PAB-MMAE

Cat. No.: HY-W190943

Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bi-Mc-VC-PAB-MMAE

Cat. No.: HY-141833

Bi-Mc-VC-PAB-MMAE consists ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCK2R Ligand-Linker Conjugates 1

Cat. No.: HY-128941

CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL2-SN-38

Cat. No.: HY-126350

CL2-SN-38 is a part of the **antibody drug conjugate (ADC)**, can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is a DNA topoisomerase I inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CL2A-SN-38

Cat. No.: HY-128946

CL2A-SN-38 is a **drug-linker conjugate** composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types.

Purity: 98.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CL2E-SN38

Cat. No.: HY-139909

CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (**ADC**). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL2E-SN38 TFA

Cat. No.: HY-139909A

CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (**ADC**). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cys-mcMMAD

Cat. No.: HY-15750

Cys-mcMMAD is a drug-linker conjugate for ADC. MMAD is a potent tubulin inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

DBA-DM4

Cat. No.: HY-128960

DBA-DM4 is a **drug-linker conjugate** composed of a potent a tubulin inhibitor DM1 and a linker SPDP to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-(PEG)3-VC-PAB-MMAE

Cat. No.: HY-111012

DBCO-(PEG)3-VC-PAB-MMAE is made by MMAE conjugated to DBCO-(PEG)3-vc-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mg

DBCO-(PEG2-VC-PAB-MMAE)2

Cat. No.: HY-126690

DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-Ahx-DM1

Cat. No.: HY-136260

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-GGFG-DX8951

Cat. No.: HY-134723

DBCO-PEG4-GGFG-DX8951 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the non-cleavable ADC linker DBCO-PEG4-GGFG.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-MMAF

Cat. No.: HY-133492

DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

DBCO-PEG4-VA-PBD

Cat. No.: HY-133433

DBCO-PEG4-VA-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DBCO-PEG4-Val-Cit-PAB-MMAF

Cat. No.: HY-130990

DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBCO-PEG4-VC-PAB-DMEA-PNU-159682

Cat. No.: HY-126691

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for **ADC**, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

DBCO-PEG4-VC-PAB-MMAE

Cat. No.: HY-136314

DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a **tubulin polymerization** inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in th e synthesis of antibody-drug c onjugates (**ADC**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DBM-MMAF

Cat. No.: HY-136287

DBM-MMAF is a drug-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Deruxtecan

Cat. No.: HY-13631E

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.



Purity: 99.43%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg

Desmethyl Vc-seco-DUBA

Cat. No.: HY-131085

Desmethyl Vc-seco-DUBA consists a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DGN549-C

Cat. No.: HY-136297

DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel **DNA-alkylating** cytotoxic payload and can be used in the synthesis of antibody-drug conjugates (**ADC**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DGN549-L

Cat. No.: HY-145365

DGN549-L is a DNA alkylator and can be utilized for antibody conjugation at lysine residues. DGN549-L can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM1-PEG4-DBCO

Cat. No.: HY-136261

DM1-(PEG)4-DBCO is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (**ADC**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DM4-SMCC

Cat. No.: HY-126494

DM4-SMCC is a **drug-linker conjugate for ADC** with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

DM4-SPDP

Cat. No.: HY-126493

DM4-SPDP is a drug-linker conjugate composed of a potent antitubulin agent DM4 and a linker SMCC to make antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doxorubicin-SMCC

Cat. No.: HY-116063

Doxorubicin-SMCC is a **drug-linker conjugate for ADC**. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FCHFHS-ST7612AA1

Cat. No.: HY-112805

FCHFHS-ST7612AA1 is a part of antibody drug conjugates (**ADCs**) charged with **HDAC** inhibitor by a linker, shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-Val-Cit-PAB-Duocarmycin TM

Cat. No.: HY-126532

Fmoc-Val-Cit-PAB-Duocarmycin TM is a **drug-linker conjugate for ADC** by using the antitumor antibiotic, Duocarmycin TM, linked via Fmoc-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Fmoc-Val-Cit-PAB-MMAE

Cat. No.: HY-19811

Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

Purity: 95.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gemcitabine-O-Si(di-iso)-O-Mc

Cat. No.: HY-130812

Gemcitabine-O-Si(di-iso)-O-Mc is a **drug-linker conjugate for ADC** with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gly3-VC-PAB-MMAE

Cat. No.: HY-131056

Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM

Cat. No.: HY-145663

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a drug-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Asparagine-N-Fmoc,N-beta-trityl-15N2

Cat. No.: HY-W002327S1

L-Asparagine-N-Fmoc,N-beta-trityl-15N2 is a 15N-labeled Deruxtecan. Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Lysine-15N dihydrochloride

Cat. No.: HY-W009762S7

L-Lysine-15N (dihydrochloride) is a 15N-labeled Deruxtecan. Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lys-Nε-SPDB-DM4

Cat. No.: HY-141596

Lys-Nε-SPDB-DM4 is a **drug-linker conjugate** composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody drug conjugate (ADC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lys-SMCC-DM1

(Lys-Nε-MCC-DM1)

Cat. No.: HY-101982

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a linker-payload component that has the potential to inhibit tubulin polymerization.Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a human epidermal growth factor receptor 2 (HER2)-targeting ADC with a tubulin polymerization inhibitor DM1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MAC glucuronide phenol-linked SN-38

Cat. No.: HY-128943

MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) drug linker.



Purity: 96.26%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

MAC glucuronide α-hydroxy lactone-linked SN-38

Cat. No.: HY-128942

MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAC-VC-PABC-ST7612AA1

Cat. No.: HY-112806

MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (**ADCs**) charged with **HDAC** inhibitor by a linker, shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-(CH2)5-Val-Cit-PAB-Eribulin

Cat. No.: HY-139642

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Mal-C2-Gly3-EDA-PNU-159682

Cat. No.: HY-126688

Mal-C2-Gly3-EDA-PNU-159682, a drug-linker conjugate for **ADC**, consists a cleavable ADC linker Mal-C2-Gly3-EDA and a potent ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-C6-α-Amanitin

Cat. No.: HY-126683

Mal-C6-α-Amanitin is a **drug-linker conjugate for ADC** with potent antitumor activity by using α-Amanitin (an RNA polymerase Ⅱ inhibitor), linked via the ADC linker Mal-C6.



Purity: 95.37%
Clinical Data: No Development Reported
Size: 5 mg

MAL-di-EG-Val-Cit-PAB-MMAE

Cat. No.: HY-100567

MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent **tubulin** inhibitor (MMAE).



Purity: 98.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MAL-di-EG-Val-Cit-PAB-MMAF

Cat. No.: HY-128711

MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F).



Purity: 98.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Mal-PEG2-VCP-Eribulin

Cat. No.: HY-128870

Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG4-VA-PBD

Cat. No.: HY-126685

Mal-PEG4-VA-PBD is a drug-linker conjugate for **ADC** by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mal-PEG4-VC-PAB-DMEA-PNU-159682

Cat. No.: HY-126687

Mal-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for **ADC**, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA

Cat. No.: HY-126684

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a drug-linker conjugate for **ADC** by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan

Cat. No.: HY-145399

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a conjugate used to synthesis ADC.
Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan comprises topoisomerase inhibitor derivative with a linker for connecting to a ligand unit (extracted from patent US20200306243A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG8-Val-Cit-PAB-MMAE

Cat. No.: HY-141156

Mal-PEG8-Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC**. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162).



Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682

Cat. No.: HY-126689

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for **ADC**, consists the ADC linker Mal-Phe-C4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-Phe-C4-VC-PAB-MMAE

Cat. No.: HY-126686

Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent **tubulin** inhibitor, is a toxin payload in antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mal-VC-PAB-ABAEP-Azonafide

Cat. No.: HY-126692

Mal-VC-PAB-ABAEP-Azonafide is a **drug-linker conjugate for ADC** with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-VC-PAB-DM1

Cat. No.: HY-126682

Mal-VC-PAB-DM1 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

MB-VC-MGBA

Cat. No.: HY-136289

MB-VC-MGBA is a drug-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Alkyl-Hydrazine Modified MMAF

Cat. No.: HY-128961

MC-Alkyl-Hydrazine Modified MMAF is a **drug-linker conjugate for ADC** with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-betaglucuronide-MMAE-1

Cat. No.: HY-136317

MC-betaglucuronide-MMAE-1 is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-betaglucuronide-MMAE-2

Cat. No.: HY-136321

MC-betaglucuronide-MMAE-2 is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mc-Dexamethasone

Cat. No.: HY-136290

Mc-Dexamethasone is a **drug-linker conjugate for ADC**. Mc-Dexamethasone is made toxin Dexamethasone (HY-14648) conjugated to the non-cleavable MC linker. Dexamethasone is a glucocorticoid receptor agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-DM1

Cat. No.: HY-136286

MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-DOXHZN ((E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone)

Cat. No.: HY-16261A

MC-DOXHZN ((E/Z)-Aldoxorubicin) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-DOXHZN hydrochloride ((E/Z)-Aldoxorubicin hydrochloride; Doxorubicin(6-maleimidocaproyl)hydrazone hydrochloride)

Cat. No.: HY-16261B

MC-DOXHZN ((E/Z)-Aldoxorubicin) hydrochloride is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

MC-GGFG-DX8951

Cat. No.: HY-114233

MC-GGFG-DX8951 is a **drug-linker conjugate for ADC** with antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Mc-MMAD

Cat. No.: HY-15740

Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a drug-linker conjugate for ADC.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E)

Cat. No.: HY-15741

Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent **tubulin** inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.



Purity: 96.47%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mg

MC-SN38

Cat. No.: HY-136170

MC-SN38 is a drug-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody drug conjugate (ADC).



Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MC-Sq-Cit-PAB-Dolastatin10

Cat. No.: HY-128894

MC-Sq-Cit-PAB-Dolastatin10 is a **drug-linker conjugate for ADC** with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Sq-Cit-PAB-Gefitinib

Cat. No.: HY-128893

MC-Sq-Cit-PAB-Gefitinib is a **drug-linker conjugate for ADC** with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-Auristatin E

Cat. No.: HY-128899

MC-Val-Cit-PAB-Auristatin E is a **drug-linker conjugate for ADC** with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MC-Val-Cit-PAB-carfilzomib iodide

Cat. No.: HY-128903

MC-Val-Cit-PAB-carfilzomib iodide is a **drug-linker conjugate for ADC** with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

MC-Val-Cit-PAB-clindamycin

Cat. No.: HY-128907

MC-Val-Cit-PAB-clindamycin is a **drug-linker conjugate for ADC** with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-dimethylDNA31

Cat. No.: HY-128905

MC-Val-Cit-PAB-dimethylDNA31 is a **drug-linker conjugate for ADC** with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-duocarmycin chloride

Cat. No.: HY-128904

MC-Val-Cit-PAB-duocarmycin chloride is a **drug-linker conjugate for ADC** with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-Val-Cit-PAB-DX8951

Cat. No.: HY-145929

MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-Val-Cit-PAB-Indibulin

Cat. No.: HY-128908

MC-Val-Cit-PAB-Indibulin is a **drug-linker conjugate for ADC** with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-Val-Cit-PAB-MMAF

(Vc-MMAF)

Cat. No.: HY-112786

MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a **drug-linker conjugate for ADC** with antitumor activity by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

MC-Val-Cit-PAB-Retapamulin

Cat. No.: HY-128906

MC-Val-Cit-PAB-Retapamulin is a **drug-linker conjugate for ADC** with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-rifabutin

Cat. No.: HY-128909

MC-Val-Cit-PAB-rifabutin is a **drug-linker conjugate for ADC** with potent antitumor activity by using rifabutin (an DNA-dependent RNA polymerase inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-Val-Cit-PAB-vinblastine

Cat. No.: HY-128902

MC-Val-Cit-PAB-vinblastine is a **drug-linker conjugate for ADC** with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.



Purity: 90.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-VC(S)-PABQ-Tubulysin M

Cat. No.: HY-128910

MC-VC(S)-PABQ-Tubulysin M is a **drug-linker conjugate for ADC** with potent antitumor activity by using Tubulysin M (a tubulin inhibitor), linked via the ADC linker MC-VC(S)-PABQ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-VC-PAB-MMAD

Cat. No.: HY-136316

MC-VC-PAB-MMAD is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker MC-VC-PAB.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Mc-VC-PAB-SN38

Cat. No.: HY-131057

Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MC-VC-PAB-Tubulysin M

Cat. No.: HY-136313

MC-vc-PAB-Tubulysin M consists a cleavable ADC linker (MC-vc-PAB) and a cytotoxic tubulin inhibitor Tubulysin M (HY-N7053).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MC-VC-PABC-Aur0101

Cat. No.: HY-128955

MC-VC-PABC-Aur0101 is a **drug-linker conjugate for ADC** with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MC-VC-PABC-DNA31

Cat. No.: HY-128897

MC-VC-PABC-DNA31 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MC-VC-PABC-SP 141

Cat. No.: HY-136320

MC-VC-PABC-SP 141 is a **drug-linker conjugate for ADC** with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCC-DM1

Cat. No.: HY-132250

MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCC-Modified Daunorubicinol

Cat. No.: HY-128959

Daunorubicinol is a **drug-linker conjugate for ADC** with potent antitumor activity by using Aur0101 (DNA Topoisomerase II inhibitor), linked via the ADC linker.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

McMMAF

(Maleimidocaproyl monomethylauristatin F)

Cat. No.: HY-15578

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMAE-SMCC

Cat. No.: HY-135660

MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Modified MMAF-C5-COOH

Cat. No.: HY-141593

Modified MMAF-C5-COOH is a drug-linker conjugate for ADC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT

Cat. No.: HY-132161

MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker compound extracted from patent WO2019195665A1, example 4-1.
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a **drug-linker conjugate for antibody-drug conjugate (ADC)**.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT

Cat. No.: HY-145943

MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT has the potential for cancer and autoimmune disease research.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG3-vc-PAB-MMAE

Cat. No.: HY-100874

N3-PEG3-vc-PAB-MMAE is a synthesized **drug-linker conjugate for ADC** that incorporates the MMAE (a tubulin inhibitor) and 3-unit PEG linker.
N3-PEG3-vc-PAB-MMAE shows potent antitumor activity.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

N3-PEG4-DYKDDDD-Doxorubicin

Cat. No.: HY-133586

N3-PEG4-DYKDDDD-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-DYKDDDD.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG4-YPYDVPDYA-Doxorubicin

Cat. No.: HY-131090

N3-PEG4-YPYDVPDYA-Doxorubicin is a drug-linker conjugate for ADC with potent antitumor activity by using the cytotoxic anthracycline antibiotic, Doxorubicin, linked via the cleavable linker N3-PEG4-YPYDVPDYA.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N3-PEG8-Phe-Lys-PABC-Gefitinib

Cat. No.: HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NAMPT inhibitor-linker 1

Cat. No.: HY-112615

NAMPT inhibitor-linker 1 is a drug-linker conjugates for **ADC**, composed of an **NAMPT** inhibitor as a payload, and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NAMPT inhibitor-linker 2

Cat. No.: HY-112616

NAMPT inhibitor-linker 2 is a drug-linker conjugates for **ADC**, composed of an **NAMPT** inhibitor as a payload, and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nitro-PDS-Tubulysin M

Cat. No.: HY-128896

Nitro-PDS-Tubulysin M is a **drug-linker conjugate for ADC** with potent antitumor activity by using Tubulysin M (a tubulin polymerization inhibitor), linked via the ADC linker Nitro-PDS.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OSu-Glu-VC-PAB-MMAD

Cat. No.: HY-136315

OSu-Glu-VC-PAB-MMAD is a **drug-linker conjugate for ADC** with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker OSu-Glu-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PEG4-aminooxy-MMAF

Cat. No.: HY-128968

PEG4-aminooxy-MMAF is a **drug-linker conjugate for ADC** with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.



Purity: 97.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PNU-EDA-Gly5

Cat. No.: HY-145078

PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSMA-ALB-56

Cat. No.: HY-141536

PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSMA-Val-Cit-PAB-MMAE

Cat. No.: HY-141860

PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rha-PEG3-SMCC

Cat. No.: HY-142740

Rha-PEG3-SMCC (compound 13) is a **drug-linker&n bsp;conjugate for ADC** with ;potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC-VC-PAB-DM1

Cat. No.: HY-126693

SC-VC-PAB-DM1 is a **drug-linker conjugate for ADC** with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC-VC-PAB-MMAE

Cat. No.: HY-126681

SC-VC-PAB-MMAE is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SGD-1910

Cat. No.: HY-101162

SGD-1910 is a **drug-linker conjugate for ADC** by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala.



Purity: 95.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMCC-DM1

(DM1-SMCC)

Cat. No.: HY-101070

SMCC-DM1 (DM1-SMCC) is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody drug conjugate (ADC).



Purity: 98.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SN38 NHS ester

Cat. No.: HY-145732

SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SPB

Cat. No.: HY-104025

SPB is a drug-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SPDB-DM4

Cat. No.: HY-12460

SPDB-DM4 is a **drug-linker conjugate for ADC** by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SPP-DM1

Cat. No.: HY-126491

SPP-DM1 is a **drug-linker conjugate for ADC** with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Sulfo-PDBA-DM4

Cat. No.: HY-128954

Sulfo-PDBA-DM4 is a **drug-linker conjugate** composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody drug conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfo-SPDB-DGN462

Cat. No.: HY-136291

Sulfo-SPDB-DGN462 is a **drug-linker conjugate for ADC**. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

sulfo-SPDB-DM4

Cat. No.: HY-101141

sulfo-SPDB-DM4 is a **drug-linker conjugate for ADC** by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SuO-Glu-Val-Cit-PAB-MMAE

Cat. No.: HY-130989

SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SuO-Val-Cit-PAB-MMAE

Cat. No.: HY-100566

SuO-Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC** by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tesirine

(SG3249)

Cat. No.: HY-128952

Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics.



Purity: 97.96%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg

Thalidomide-NH-PEG7

Cat. No.: HY-130648

Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for **ADC**. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLR7/8 agonist 4 hydroxy-PEG10-acid

Cat. No.: HY-139018

TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a **drug-linker conjugate for ADC** with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the cleavable ADC linker hydroxy-PEG10-acid (HY-133307).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride

Cat. No.: HY-139018A

TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a **drug-linker conjugate for ADC** with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the cleavable ADC linker hydroxy-PEG10-acid (HY-133307).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Val-Cit-PAB-MMAE

Cat. No.: HY-100374

Val-Cit-PAB-MMAE is a **drug-linker conjugate for ADC**. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent **mitotic** inhibitor by inhibiting tubulin polymerization.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mg

Vat-Cit-PAB-Monomethyl Dolastatin 10

Cat. No.: HY-126492

Vat-Cit-PAB-Monomethyl Dolastatin 10 is a **drug-linker conjugate for ADC** with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Vc-MMAD

Cat. No.: HY-15742

Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a drug-linker conjugate for ADC.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 1 mg

Vc-seco-DUBA

(SYD985)

Cat. No.: HY-128957

Vc-seco-DUBA (SYD985) is a **drug-linker conjugate for ADC** with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.



Purity: 99.80%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

VcMMAE

(MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE)

Cat. No.: HY-15575

VcMMAE (mc-vc-PAB-MMAE) is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg (1 mg x 5), 10 mg (1 mg x 10)

VCP-Eribulin

Cat. No.: HY-128871

VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based drug for antibody conjugates.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vipivotide tetraxetan

(PSMA-617) **Cat. No.:** HY-117410

Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen **(PSMA)** inhibitor, with a K_i of 0.37 nM.



Purity: 98.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Xanthine-13C,15N2

Cat. No.: HY-W017389S

Xanthine-13C,15N2 is a 15N-labeled and 13C-labled Deruxtecan. Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC-Linker Conjugates for PAC

PROTAC-Linker for PROTAC-antibody Conjugates

PROTAC-linker Conjugate for PAC comprises an antibody conjugated via a linker to a PROTAC. The PROTAC-Antibody Conjugate (PAC) molecules comprise an antibody conjugated via a linker (L1) to a PROTAC, wherein the PROTAC comprises an ubiquitin E3 ligase binding groug ("E3LB"), a linker ("L2") and a protein binding group ("PB"). To obtain a PAC having potent efficacy and a desirable therapeutic index, the following components are provided. 1. Antibody (Ab): The antibody portion of a PAC can target a cell that expresses an antigen whereby the antigen specific PAC is delivered intracellularly to the target cell, typically through endocytosis While PACs that comprise an antibody directed to an antigen that is not found on the cell surface may result in less specific intracellular delivery of the PROTAC portion into the cell, the PAC may still undergo pinocytosis. 2. Linkers (L1): A"linker" (L1) is a bifunctional or multifunctional moiety that can be used to link one or more PROTAC moieties (D) to an antibody (Ab) to form a PAC. In some embodiments, PACs can be prepared using a L1 having reactive functionalities for covalently attaching to the PROTAC and to the antibody. 3. PROTAC(D).

PROTAC-Linker Conjugates for PAC

PAC

Cat. No.: HY-112100

PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).

Purity: 98.17%
Clinical Data: No Development Reported
Size: 1 mg

PROTAC BRD4 degrader for PAC-1

Cat. No.: HY-129938

PROTAC BRD4 degrader for PAC-1 (compound 5), a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 and disulfide-containing linker.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 1 mg

PROTAC BRD4 Degrader-5-CO-PEG3-N3

Cat. No.: HY-133736

PROTAC BRD4 Degrader-5-CO-PEG3-N3 (Compound 2) is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader GNE-987 and PEG-based linker.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mg